Fewer than five prescriptions for unlicensed cannabis medicines have been issued on the NHS.
Approaching five years since medical cannabis was legalised in the UK, a new BBC documentary accuses the government of misleading the public over its availability on the NHS.
On 1 November, 2023 medical cannabis will have been legally available on prescription in the UK for five years.
In that time, however, fewer than five prescriptions for unlicensed cannabis medicines have been obtained through the NHS, as confirmed by an FOI request made by Cannabis Health in August 2023.
The same request revealed that between November 2018-November 2022, over 140,000 prescriptions for unlicensed products were issued privately, with around 30,000 people now thought to have been prescribed the treatment.
A BBC documentary, which aired on iPlayer on Wednesday 13 September, highlights how despite an exception having been made for a select few patients, millions are still forced to fund it themselves or turn to the illegal market.
Hannah Deacon’s son Alfie Dingley was the first child in the UK to obtain a full licence for whole-plant cannabis through the NHS in 2018.
Alfie, who is shown in the documentary taking his cannabis oil at breakfast, playing football and heading off on the bus to school, has now been seizure free for over three years.
“I felt my son’s legacy was that millions of people would now get access to the treatment that he had, which was a wonderful feeling,” Deacon said, reflecting on how little has changed since he got his prescription.
“I think they changed the law to take the wind out of my sails because the campaign was very effective. All of the parents who are now trying to get access for their children’s epilepsy are blocked at every turn. It broke my heart.”
Patients forced to choose between food or medicine
The documentary also hears from patients who are prescribed cannabis privately but face a daily struggle to fund it.
Breast cancer survivor, Amanda Lowe, explains how cannabis helps her manage the nerve pain resulting from 14 operations, but sometimes she is forced to choose between eating or accessing her medication.
Meanwhile, Tourette’s patient Conor Ryder, says his prescription is eating into his savings.
“It’s about £300 a month,” he said.
“We scrimp and save where we can in order to be able to afford it basically, but we are going through our savings. I’m hoping that soon I’ll be able to work and maybe be able to manage it because that’s the only way if it doesn’t become available on the NHS.”
A ‘difficult position’ for doctors
Experts interviewed by the BBC claim it was misleading of the government to legalise medical cannabis without the right infrastructure or regulations in place to allow doctors to prescribe.
Dr David McCormick, a paediatric consultant at King’s College London, said it left doctors like himself in a ‘difficult position’.
“The message went out that doctors can now prescribe cannabis-based medicinal products, but as doctors that has left us in a difficult position, because in truth we need to apply for the cannabis to be approved by NHS England,” he told the BBC.
“I would like to see better evidence for their efficacy and safety, at this I don’t quite feel the evidence for me is there.
“That does mean we find ourselves in a strange situation right now, in the sense that these products are not available within our much-loved NHS, free at the point of need.”
Dr McCormick added: “I do have some concerns about the private industry, mostly because I don’t know what these products contain, how much my patients are getting and what effects that might have on them in the long term.”
Explaining some of the barriers which are currently preventing doctors from prescribing, Professor David Nutt, founder of Drug Science and former scientific advisor on drugs to the government, said: “Most doctors will not prescribe any medicine until two things happen; the first is that a drug company does a trial and tells them that they can prescribe it because they’ve got a licence, and the second is that NICE issues guidelines to say it’s cost effective, and with medical cannabis, neither of those things have happened.”
Professor Nutt described the current situation as ‘outrageous’, adding that by only permitting specialist consultants to prescribe rather than GPs, the legislation has limited access even further.
“It was almost as if they gave it with one hand and took it away with the other,” he said.
“Unfortunately constraining prescriptions to consultants made it almost unavailable to the people that really need it, the people who are in primary care.”
He added: “It’s a scandal that so little has happened in the NHS.”
The Institute of Cannabis Research (ICR) is a distinguished establishment located at Colorado State University Pueblo. It is devoted to the study of cannabis, a plant with extensive potential and wide-ranging uses in the fields of medicine, industry, and recreational use. The institute was established in 2016, marking a significant step forward in the scientific and scholarly research of cannabis and hemp.
The purpose of the ICR is to generate new knowledge in the science, societal impacts, and potential benefits and risks associated with cannabis and its derivatives. The institute’s scope of research is broad and comprises areas like biology, chemistry, horticulture, engineering, and psychology.
ICR’s research findings are expected to advance our understanding of the medicinal values of cannabis, its impact on human health, and also the societal and economic effects of the legalization of cannabis. Furthermore, it seeks to provide comprehensive, unbiased information that can be used by legislators, healthcare providers, industry, and the public.
Being located in Colorado, a state that has legalized both medical and recreational marijuana, the ICR is in a unique position to conduct this type of research. The institute collaborates with local, national, and international academic institutions, government agencies, and industries, ensuring a multidisciplinary approach to its research.
In addition to research, the ICR is committed to educating the public about cannabis. It organizes annual conferences to disseminate research findings, hosts public education events, and publishes scholarly papers to share the findings of its research with the world.
The ICR’s research is helping to advance our understanding of the potential benefits and risks of cannabis use. Its findings are informing public policy decisions about cannabis1. The ICR is a valuable resource for anyone interested in learning more about the science of cannabis.
The internationally acclaimed Journal of Cannabis Research is a preeminent, open-access, and peer-reviewed scholarly publication that warmly invites submissions from around the globe, addressing a comprehensive spectrum of topics related to cannabis. This world-renowned journal, a pioneering force in its field, is sponsored and supported by the highly esteemed Institute of Cannabis Research at Colorado State University-Pueblo, which itself is recognized for its rigorous and innovative research in the field of cannabis.
The Journal of Cannabis Research has been monumental in its commitment in providing an inclusive platform for researchers, scholars, and academics to share their unique findings, perspectives, and insights on the dynamic and rapidly evolving field of cannabis research. In its quest for truth and knowledge, the journal shows a unique versatility, not just limiting itself to a single aspect or a narrow field of cannabis research, but inviting an expansive variety of topics.
The Journal, through its published papers, thoroughly investigates and critically analyses every facet of cannabis research — from examining the medical implications and therapeutic applications of cannabis to discussing the legal and socio-economic impacts of cannabis legalization. It delves into the role of cannabis in public health, looks at the genetic and environmental factors influencing cannabis growth, and explores the historical and cultural contexts of cannabis use. It also provides an in-depth analysis of the economic and commercial aspects of cannabis, including its production, distribution, and market trends.
The Journal of Cannabis Research publishes a broad and diverse range of articles. It does not restrict itself to any specific type of research or discipline but instead embraces a wider scope that mirrors the multifaceted nature of cannabis research. Included but not limited to, its publications encompass original research papers, comprehensive review articles, short communications, case studies, and technical notes.
The original research articles provide a detailed account of the latest discoveries and advancements in cannabis research, contributing to the growing body of knowledge in the field. The review articles, on the other hand, offer an exhaustive assessment of the current literature, summarizing and synthesizing the most recent developments, theories, and debates surrounding cannabis.
Short communications provide a platform for swift dissemination of significant research findings or novel ideas that may not warrant a full article but are still important contributions to the field. Case studies offer a detailed, in-depth examination of particular instances or scenarios related to cannabis, providing valuable insights and practical applications. Lastly, technical notes share new methodologies, techniques, or software related to cannabis research, promoting better research practices and innovation in the field.
Therefore, the Journal of Cannabis Research, with its broad scope, commitment to diversity, and dedication to knowledge dissemination, continues to be an invaluable resource for anyone interested or involved in the multifaceted field of cannabis research. It provides an excellent platform for scholars to share their research, engage in scientific discourse, and contribute to the global understanding of cannabis and its implications.
Agriculture, Biology, and Commercial/Industrial Uses of Cannabis:
Agriculture: Cannabis is a versatile plant cultivated for its fibers, seeds, and cannabinoid-rich flowers. Varieties like hemp are grown for their industrial applications, including textiles, paper, and biofuels.
Biology: Cannabis plants contain numerous compounds, including cannabinoids, terpenes, and flavonoids. The primary psychoactive compound is delta-9-tetrahydrocannabinol (THC), while cannabidiol (CBD) is non-psychoactive and known for its potential health benefits.
Commercial and Industrial Uses: Hemp fibers are used in textiles and construction materials. Hemp seeds are a nutritious source of food, while cannabinoids are the foundation of the medicinal and recreational cannabis industry.
Endocannabinoid System:
The endocannabinoid system (ECS) is a complex network of receptors, endocannabinoids, and enzymes. It plays a crucial role in regulating various physiological processes, including mood, appetite, pain, and inflammation. Cannabinoids from the cannabis plant interact with the ECS.
Pharmacology and Toxicology of Cannabis and Cannabinoids:
Pharmacology: Cannabis compounds interact with receptors in the body, producing a wide range of effects. Understanding the pharmacology helps in utilizing these compounds for therapeutic purposes.
Toxicology: Research explores the potential adverse effects of cannabis, particularly in high doses or with prolonged use.
Epidemiology, Public Health, and Social Impacts:
Epidemiology: Studies investigate the prevalence of cannabis use, patterns, and associated health outcomes.
Public Health: Public health aspects focus on educating the public about responsible cannabis use and minimizing potential harm.
Social Impacts: Cannabis legalization has various social consequences, from criminal justice reform to changes in community dynamics.
Prevention, Screening, Diagnosis, and Treatment of Cannabis-Related Disorders:
These aspects involve strategies to prevent problematic cannabis use, identifying signs of misuse, diagnosing disorders like cannabis use disorder, and providing appropriate treatments.
Therapeutic Uses of Cannabis and Cannabinoids:
Cannabis and cannabinoids are increasingly used for various medical conditions, such as chronic pain, epilepsy, multiple sclerosis, and cancer-related symptoms.
Business, Economic, and Environmental Aspects of the Cannabis Industry:
The cannabis industry has seen significant growth, creating jobs and economic opportunities. However, it also raises environmental concerns due to energy-intensive indoor cultivation.
Historical, Public Policy, Legal, Ethical, and International Aspects:
The history of cannabis includes its use in medicine and its prohibition in many countries. Public policies and laws vary widely, and ethical debates include issues like access and responsible use. The international dimension involves treaties and agreements governing cannabis.
Cannabinoids are broadly defined as comprising all constituents of the cannabis plant (phytocannabinoids, terpenes, and flavonoids) as well as synthetic cannabinoids. The Journal accepts a variety of submission types, including original research, technical notes, case reports, reviews, and commentaries.
The Journal of Cannabis Research is distinctly unique and stands out in the realm of scientific publications due to its comprehensive, multidisciplinary approach towards researching cannabis. This fully open access journal is leading the way in the field, not only due to its focus on medical and scientific research on cannabis but also its dedication to investigating the wider implications of the plant’s use and its fluctuating legal status.
This highly respected journal seeks to provide a comprehensive understanding of cannabis’ diverse effects and influences. Within its pages, it addresses the sociological, commercial, agricultural, legal, environmental, and ethical impacts that stem from the use of cannabis. Hence, the Journal strives to encapsulate as much knowledge as possible about this multifaceted plant, providing a panoramic view of the issue.
The Journal of Cannabis Research’s primary goal extends beyond merely publication. It aims to serve as a cross-disciplinary platform that nurtures innovation and encourages collaboration. By bringing together experts from multidisciplinary fields, it aims to stimulate public discourse on this pressing concern and propel further research in this dynamic and exciting area.
But its reach doesn’t stop within the academic community. By being freely accessible, the Journal ensures that crucial and authoritative information pertaining to all aspects of cannabis is available to both the academic community and public policy makers in a timely manner. This strategy is particularly instrumental in facilitating informed decision-making by lawmakers, public officials, and those tasked with formulating public policy.
The Journal of Cannabis Research is helmed by the esteemed clinical pharmacologist and cannabis researcher, Professor David A. Gorelick, MD, PhD. Known for his expertise in clinical psychiatry, substance use, and scientific conduct and ethics, Professor Gorelick leads this pioneering publication with experience and intellectual rigor.
Under his guidance, the Journal relies on the support and contributions of a prestigious Editorial Board. This includes leading researchers and investigators from around the world who are at the forefront of cannabis research. Among these distinguished contributors are pre-eminent cannabis scientists Professor Raphael Mechoulam, PhD, and Professor Lumír Hanuš, PhD. Their invaluable insights and extensive experience in the field of cannabis research contribute significantly to the Journal’s authoritative position in the field.
In conclusion, the Journal of Cannabis Research is much more than just a scientific publication. It is an influential platform that encourages cross-disciplinary collaboration and stimulates public discourse. It ensures that key stakeholders—be it clinicians, biological scientists, social scientists, lawyers, economists, business experts, ethicists, public policy experts, or public officials—have timely and open access to the most authoritative and comprehensive information about cannabis. This is crucial for informed decision-making in various fields impacted by the use and legal status of cannabis.
For the past year and a half, medical cannabis company CEO Gary Long has spent a lot of his time reassuring Georgia’s small-town mayors about what will soon be coming to their local pharmacy: medical marijuana.
“They think that we’re going to be selling joints out of a pharmacy or something and that’s not right,” said Long, whose company, Botanical Sciences, is one of two licensed medical cannabis production companies in Georgia.
Contrary to what anxious local leaders may think, weed sodas won’t be sold alongside the Coke Zero at their local pharmacy. But by the end of the year, people who meet the extremely narrow criteria spelled out in Georgia’s conservative medical cannabis law, are expected to have the opportunity to buy low-dose THC products at their pharmacy — a first in the United States.
The Georgia Board of Pharmacy is currently processing applications from pharmacies around the state that want to sell low-dose THC products. Under Georgia law, the THC content can only be up to 5%. THC, or tetrahydrocannabinol, is the part of the cannabis plant that produces a “high” — one of the key reasons doctors may suggest patients use medical cannabis to help with pain, nausea, insomnia and other issues. Products can include THC oil, tinctures, topicals, capsules and lozenges.
National chains such as CVS and Walmart won’t be selling THC products in Georgia, but Long said 130 local pharmacies have already agreed to sell his product exclusively. The state has more than 400 independent pharmacies and many seem interested in getting the special THC sale license, according to the professional association representing those stores. That would put 90% Georgians within a 30-minute drive from a pharmacy that could sell it, Long said.
Other states, such as Connecticut, require a pharmacist to be on staff at the dispensaries, but pharmacies do not sell the products. There are at least three states other than Georgia that have a law on the books that would allow pharmacies to sell, but they have not implemented the law, according to Andrew Turnage, the executive director of the GA Access to Medical Cannabis Commission.
Making medical cannabis so accessible in such a traditionally conservative Deep South state likeGeorgia caught some by surprise. Last week, after Long’s company put out a news release about how products would soon be available at pharmacies, even late night television hostJimmy Kimmel did a skit about it.
“I’ve never seen anything like it,” Long said of the sudden attention. Before moving into the medicinal cannabis field, he was an executive in the more buttoned-up health care technology business.
“My 20-year-old kids were like ‘Dad, you just went viral,’ And I’m like, ‘Ok, cool,’ ” Long said.
Pharmacist Jonathan Marquesssaid patients have been asking for this kind of access for years.
“There are patients in my area that I talk to all the time who’ve been begging for this,” Marquess said.
The Georgia General Assembly approved the distribution of low-dose THC oil in 2019, but it has taken years for the state to create the regulatory infrastructure to sell it.
Creating regulations is a little tricky, experts say. While there has been a movement to change the designation, the US Drug Enforcement Administration still lists marijuana as a Schedule 1 substance, meaning that there is no current accepted medical use and a belief that it has a high potential for abuse. Since the federal government puts weed in the same category as heroin, LSD, and meth, technically, it’s illegal to sell any form of cannabis.
“It’s federally illegal for a pharmacist, I’m pretty certain, to dispense cannabis, but it’s also federally illegal to do anything with cannabis,” said Jay Wexler, a professor of law at Boston University School of Law, and the author of “Weed Rules,” a book focused on legalization. “In the cannabis space, many things are formally illegal, but the question becomes whether anybody can or is willing to do anything about it.”
The Justice Department is limited by a rider in appropriations that prohibits it from using any money to prosecute anyone who is acting consistently with state laws that allow the use of weed for medical purposes.
So within that legal gray area, Gov. Brian Kemp was able to sign off on Georgia Board of Pharmacy rules last month that cleared the way for pharmacies to apply to sell THC.
Many of Marquess’patients in the meantime have secured a doctor’s permission to register and get a card from the state needed to buy THC oil products.
“I’ve had many, many of my patients show me their cards,” said Marquess, who is vice president of the Georgia Pharmacy Association’s Academy of Independent Pharmacy, and he owns a handful of independent pharmacies with his spouse who is also a pharmacist.
Marquesssaid the lack of access to low THC products has been dangerous for his patients.
“Unfortunately, right now many of them go out of state or to places that I wouldn’t necessarily send a patient to, to get the product now,” Marquess said.
Marquess said there’s a real advantage to getting THC from a pharmacist.
“They can provide some education, some resources, and even counsel to get on the right product,” Marquess said. Patients also often seen their pharmacists more often than they see their doctors.
Turnage, the executive director of the GA Access to Medical Cannabis Commission, said he has heard from a number of states that want to replicate Georgia’s program.
“States that have adult use of recreational cannabis are struggling to preserve their medical programs and those states are reaching out to learn about the dispensing pharmacies as a potential avenue to preserve patient access in their state so that their patient program doesn’t collapse under the weight of recreational use,” Turnage said.
In states where recreational use is allowed, low THC products sometimes become difficult to find, he said, since it’s the cannabis flower that becomes the most profitable product. For a lot of patients — particularly for children — smoking, vaping or even consuming THC as an edible like a gummy is not an option, or at least not ideal, he said.
Long said he hopes Georgia will consider expanding who is eligible to get access to THC. While access in Georgia is more equitable with pharmacy sales, the law is more restrictive than most of the 38 states allow medical use of cannabis products.
“The Georgia law itself still has a long way to go,” said Aaron Smith, the executive director of the National Cannabis Industry Association. Californians have been able to buy medical cannabis since 1996 and adults there got the right to use it recreationally in 2016.
“So it’s good to see Georgia come into line with the vast majority of states that already have medical use, but other states have done it in a way that I think is more effective at actually meeting the needs of patients,” Smith said.
In states such as Massachusetts, doctors can prescribe medical marijuana for any patient they think it will help. Georgia restricts access to 16 diseases, including Alzheimer’s, some stages of cancer, PTSD, sickle cell, and Crohn’s.
Turnage said that while the products and patients able to use them are limited, expanding where patients can buy the products will matter. He said when he has been to the grand openings of the dispensaries and sees so many patients lined up outside, often they will come hug him and say thank you for making access possible.
“I’ve been really grateful for the heat this summer, because I can tell them the moisture on my face is just from sweating, they don’t have to know it’s my tears,” Turnage said. “That makes the moment and all of the difficulties to get here worth it.”
Established in the dawn of the new millennium in 2000, the University of California Center for Medicinal Cannabis Research (UC CMCR) has steadfastly been at the forefront of pioneering and advancing both scientific exploration and policy research related to the potential therapeutic benefits and limitations of cannabis and its derivatives, known as cannabinoids. The Center’s commitment to this field of study was born out of the vision to unlock the potential inherent in medicinal cannabis, with a steadfast focus on the rigorous scientific study of cannabis’s efficacy and safety for therapeutic purposes.
This distinguished institution’s work has received robust backing from the California State Legislature, lending it credibility and underscoring its importance in the sphere of medicinal cannabis research. With such authoritative support, the UC CMCR has been able to blaze a remarkable trail in the realm of cannabis-based therapy. It notably orchestrated the first therapeutic research studies using smoked cannabis in a span of twenty years, thereby breaking new ground in the field and setting precedent for future studies.
Beyond just conducting preliminary studies, the CMCR has successfully concluded crucial research that has proven instrumental in unveiling the short-term efficacy of cannabis in treating conditions such as neuropathic pain and spasticity – a muscular control disorder. The research conducted by the Center has shed light on the potential of cannabis as a therapeutic tool and has provided invaluable insights that have redefined the understanding of cannabis’s role in medicine.
The Center’s work isn’t confined to just research; it is also actively engaged in maintaining a dynamic research agenda. A testament to their commitment to the field, the Center keeps its research interests evolving with the times and the emerging trends in medicinal cannabis research, thereby ensuring its continuous relevance and influence in the field.
Over the course of its existence, the UC Center for Medicinal Cannabis Research has forged numerous fruitful collaborations with crucial Federal and State agencies. These strategic partnerships have not only increased the spectrum of the Center’s influence but have also played a profound role in shaping policy and legislation concerning medicinal cannabis. It is through these collaborative efforts that the Center has been able to significantly influence policy and ignite change in the field of medicinal cannabis research.
Today, the UC CMCR stands tall as a national beacon in the field of medicinal cannabis research. It continues to light the path for other researchers and institutions, providing a shining example of dedication to scientific rigor, collaboration, and impactful policy influence. The Center’s work doesn’t just benefit the scientific community; it also has vital implications for healthcare providers, policymakers, and patients, making it a critical player in the modern landscape of medicinal cannabis. It is without a doubt that the UC Center for Medicinal Cannabis Research will continue to shape and drive the future of cannabis research in the years to come.
Research Accomplished
The California State Legislature generously provided funding that was judiciously utilized to address specific areas that showed immense potential for producing beneficial effects of cannabis. These areas were carefully identified and delineated based on recommendations made by esteemed national bodies like the National Academy of Sciences and the Institute of Medicine Report from 1999. Additionally, the Workshop on the Medical Utility of Marijuana, an initiative by the National Institutes of Health in 1997, also provided valuable inputs on the therapeutic benefits of cannabis that required further exploration.
The focus on these particular areas of research was not arbitrary, but instead was strategically driven by the insights and guidance of the Center for Medicinal Cannabis Research (CMCR) Scientific Advisory Board (SRB). The SRB is an independent body composed of internationally recognized subject matter experts, who are at the forefront of medical cannabis research. Their expertise and extensive knowledge in the field served as an invaluable resource in directing the research efforts towards the most promising areas.
Following a rigorous review process conducted by the SRB, the CMCR embarked on a groundbreaking journey to conduct the first set of clinical trials of smoked cannabis as a therapeutic agent in over two decades. This was a significant milestone, marking a long-overdue return to research on the medical applications of cannabis. The primary areas of focus for these trials were conditions such as neuropathic pain and spasticity, which previous reports suggested could be positively impacted by the use of cannabis.
Neuropathic pain, a complex, chronic pain state generally accompanied by tissue injury, and spasticity, a condition where certain muscles are continuously contracted causing stiffness or tightness of the muscles that may interfere with normal movements, were chosen as the core focus areas for these trials based on the potential that cannabis showed for providing relief in these medical conditions.
These clinical trials initiated by the CMCR, therefore, represented a significant step towards harnessing the potential therapeutic benefits of cannabis, a natural plant compound that has been used by humans for its medicinal properties for thousands of years. The funding provided by the California State Legislature played an instrumental role in making this possible, showing a commitment to advancing our understanding of cannabis and its potential role in modern medicine. The outcomes of these studies could potentially revolutionize the treatment options for patients suffering from conditions such as neuropathic pain and spasticity, opening up new avenues for effective and possibly more tolerable treatment modalities.
The studies funded by the Center for Medicinal Cannabis Research (CMCR) were conducted across five University of California (UC) campuses – San Diego, Irvine, Los Angeles, San Francisco, and Davis. Moreover, some of these studies were also carried out in the region of San Mateo. Various branches of the University of California have been renowned for their groundbreaking research, and this foray into the field of medicinal cannabis is no exception.
The primary focus of these studies was to examine the analgesic efficacy of cannabis. The research was performed on multiple experimental models of neuropathic pain. Neuropathic pain, a complex, chronic pain condition, usually occurs when issues develop in the way the nervous system perceives and transmits pain signals. This pain can have diverse etiology, originating from various causes and conditions such as nerve damage or dysfunction.
The UC campuses and San Mateo also conducted specific studies to understand how cannabis impacts neuropathic pain related to HIV and diabetes. As these are chronic diseases with long-term effects, the neuropathic pain associated with them often becomes increasingly difficult to manage with conventional treatment methods. Thus, exploring the potential of cannabis in providing relief in such cases became a focal point of research.
Additionally, the CMCR-funded studies evaluated the efficacy of cannabis in treating spasticity in multiple sclerosis (MS). MS is a potentially disabling disease of the brain and spinal cord (central nervous system) where the immune system attacks the protective sheath (myelin) covering the nerve fibers, causing communication problems between the brain and the rest of the body. Spasticity, a symptom of MS, refers to feelings of stiffness and a wide range of involuntary muscle spasms. The struggle to manage spasticity often impacts the quality of life for people with MS, justifying the need for exploring alternative treatments like cannabis.
It’s important to mention that all these studies were designed as short-term trials, typically involving acute administration of cannabis over a brief period of a few days. This was done to ensure the results could be analyzed and interpreted within a manageable timeframe, and any immediate side effects or reactions could be noted and studied in detail.
The findings from these studies underwent rigorous scrutiny and were reviewed by experts in the field and published in peer-reviewed scientific journals. These are publications that use a panel of other scientists and researchers to ensure the studies’ accuracy and reliability before they are published. This process helps maintain the integrity of the research and ensures that only high-quality, accurate information is disseminated to the public.
The results of these studies demonstrated significant convergence, meaning that there was a consistent finding across multiple studies. Specifically, the treatment with cannabis showed a significant improvement in the symptoms being studied. This was particularly noticeable in participants who had not achieved relief from traditional treatments, signifying the potential for cannabis to fill a critical gap in the management of neuropathic pain and spasticity in multiple sclerosis. This potential makes it a promising avenue for future research and development in the field of medicinal cannabis.
For a listing of current, as well as past studies, please click here.
Education and Dissemination of Information Related to Cannabis and Cannabinoids
A key component of the mission statement of the Center for Medicinal Cannabis Research (CMCR) involves not just the research and exploration of cannabis and cannabinoids, but also a deep commitment to extensive education and the dynamic dissemination of this information. This is done in a timely manner while ensuring that the material disseminated is supported by substantial evidence. This is an essential part of the CMCR’s quest to drive awareness and understanding about the therapeutic benefits and potential of cannabis, its derivatives, and synthetic compounds, collectively referred to as cannabinoids.
CMCR recognizes the utmost need for professionals across different fields – healthcare providers, researchers, educators, policymakers, and more – to be equipped with the latest, scientifically supported information about the medicinal use of cannabis. This allows these professionals to make informed decisions, offer the best possible advice, and develop policies that take into account the most recent and reliable findings in the field of medicinal cannabis research.
Aside from professionals, the CMCR also believes in the importance of educating the general public about cannabis and its potential medical uses. Misconceptions and stigma about cannabis use are still prevalent in today’s society, despite the growing body of research pointing to its potential benefits. By providing factual, evidence-based information, CMCR hopes to dispel these myths and promote a more informed understanding of the role cannabinoids can play in health and well-being.
The CMCR is not only focused on the present. There is a keen interest in fostering the careers of promising individuals who represent the future in the field of basic and clinical medicinal cannabis research. This is a critical aspect of the CMCR’s mission, as the future of medicinal cannabis exploration largely depends on the next generation of dedicated and knowledgeable scientists.
These future professionals will be tasked with developing a deeper and more nuanced understanding of cannabis’s potential benefits, risks, and therapeutic applications. They will also further study the complex interactions between cannabis, cannabinoids, and various aspects of health, including physical, mental, and social well-being. They will also delve into how cannabis use can influence social and behavioral functioning. This research will extend the knowledge base, enabling the CMCR and others to provide even more robust, evidence-based information to professionals and the public.
In essence, through its commitment to education, information dissemination, and fostering future talent, the CMCR is unceasingly committed to advancing the understanding of cannabis and its potential medicinal benefits. It strives to ensure that this understanding is based on solid evidence, is widely accessible, and ultimately contributes to the overall enhancement of public health and societal function.
To this end we engage in a broad range of activities:
Scientific publications Public media, including print, radio and television dissemination Educational events, including the CMCR symposia series as well as presentations at various national and international symposia and scientific meetings Training. We will be establishing a pilot program (CMCR Graduate Scholars Program) to support graduate students and postdoctoral scholars with an interest in cannabinoid science, and facilitate their work with CMCR investigators.
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis INVESTIGATOR: Veena Ranganath, MD
STUDY LOCATION: University of California, Los Angeles
PROJECT TITLE: Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
FUNDING SOURCE: Center for Medicinal Cannabis Research
PROJECT TYPE: Clinical Study
STATUS: Active (Enrolling)
ABSTRACT:
Rheumatoid Arthritis (RA) is a rare autoimmune destructive arthritic disease, where patients suffer from joint pain, joint deformity, stiffness, swelling, fatigue, impaired function, and decreased quality of life. Presently, there is no cure for RA and up to 70% of RA patients are not in remission. An estimated 64 million Americans have tried cannabidiol (CBD) per 2019 Consumer Reports national survey, where 24% are taking CBD for joint pain. Preclinical data suggests a therapeutic pain effect through anti-inflammatory pathways. However, there are few studies in rheumatic diseases evaluating cannabis-related therapeutic agents, let alone CBD without delta-9-tetrahydrocannabinol (THC). Only one clinical trial with THC+CBD in RA exists with encouraging results, suggesting improvement in pain and RA disease activity. This was a short duration, non-blinded, low dose trial using nabixomol. It is unclear if the therapeutic effects were due the THC, CBD, or combination. In addition, the results were vague in discerning if nabixomol improved pain only, joint inflammation, or both.
We propose to randomize 45 RA patients on stable RA therapy with moderate to severe disease activity and evidence of musculoskeletal ultrasound (MSUS) joint inflammation, to either placebo, CBD 200mg BID, or CBD 400mg BID for 12 weeks. We hypothesize that relative to baseline, CBD will dose-dependently improve RA joint inflammation as measured by disease activity score (DAS28, a validated clinical RA outcome) and MSUS. In addition, we will evaluate if there are any biologic effects of CBD through cytokine array and immune cell sub-types. Lastly, we will evaluate for treatment emergent adverse events and tolerability during the course of the trial.
The overall goal of this proof-of-principle proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients with moderate to severe disease activity. Our proposal has added value due to our expertise in musculoskeletal ultrasound as a supplementary endpoint beyond the DAS28. The results of this study will inform a future larger clinical trial to apprise the public and physicians on whether CBD truly reduces RA synovial inflammation and provide evidence-based CBD dosing.
The Role of Cannabidiol (CBD) in Regulating Meal Time Anxiety in Anorexia Nervosa INVESTIGATORS: Guido Frank, MD
STUDY LOCATION: University of California, San Diego
PROJECT TITLE: The Role of Cannabidiol (CBD) in Regulating Meal Time Anxiety in Anorexia Nervosa: Safety, Tolerability and Pharmacokinetics
FUNDING SOURCE: Center for Medicinal Cannabis Research
PROJECT TYPE: Clinical Study
STATUS: Active (Enrolling)
ABSTRACT:
Because there are no proven treatments that normalize core symptoms in adult anorexia nervosa (AN), a disorder with high chronicity and mortality, many individuals seek out alternative approaches to care. Recent evidence has suggested that exaggerated anxiety and diminished reward or motivation to eat play a key role in causing AN symptoms and poor outcome. The endocannabinoid system is involved in the regulation of many central and peripheral functions, including appetite, food intake, and energy balance and data suggest that eating disorders are associated with alterations of the endocannabinoid system. Prior attempts to target the endocannabinoid system in AN have focused on CB1 receptor agonists like tetrahydrocannabinol (THC) that can increase anxiety. As states have legalized cannabis, THC and cannabidiol (CBD) products are being used by patients with AN. CBD is of interest given the possibility that this drug might reduce anxiety. However, there is inconsistent evidence on CBD’s impact on appetite, which is highly relevant in treatment of AN. This project would be the first study to utilize pure, synthesized CBD to investigate the safety, tolerability, and pharmacokinetics in adult patients with AN. We propose a placebo-controlled, randomized, double-blind, pilot study, to evaluate and compare the acute and maintenance pharmacological effects of CBD at various doses compared to placebo in adult patients with AN. Our primary aim is to characterize CBD’s pharmacokinetic and safety profile in patients with AN as well as the clinical effect of CBD on 1) anxiety; 2) on AN symptoms, and 3) on restrictive eating behavior using a test meal. Knowing the safety concerns of CBD has immediate implications on clinical treatment, including effects on weight restoration, and if well tolerated and shown to have the potential to alleviate anxiety, CBD would be an important treatment to further investigate in a clinical trial.
The Effects of Cannabidiol (CBD) on Symptoms of Severe Autism INVESTIGATOR: Doris Trauner, MD STUDY LOCATION: University of California, San Diego
PROJECT TITLE: The Effects of Cannabidiol (CBD) on Symptoms of Severe Autism
FUNDING SOURCE: Wholistic Research and Education Foundation
PROJECT TYPE: Clinical Study
STATUS: Active (Enrollment Complete)
ABSTRACT:
This clinical trial is examing if and how cannabidiol (CBD), a chemical found in the cannabis plant, provides therapeutic benefit to children with severe autism spectrum disorder (ASD). The trial is funded by a grant from the Ray and Tye Noorda Foundation in partnership with and based on recommendations from the Wholistic Research and Education Foundation.
ASD affects an estimated one in 68 children in the United States, primarily boys. CBD is a major chemical compound found in cannabis. It does not produce the “highness” caused by THC but interacts with the body’s endocannabinoid system; a network that regulates diverse physiological and cognitive processes.
The goals of the study are to determine 1) if CBD is safe and tolerable and whether it helps with the symptoms of ASD; 2) whether and how CBD alters neurotransmitters and/or improves brain connectivity; and 3) whether biomarkers of neuro-inflammation, also associated with ASD, are altered by CBD.
The clinical trial consists of 30 children, ages eight to 12 years, with a confirmed diagnosis of moderate to severe autism. They must be free of other neurological conditions, such as epilepsy, and in general good health.
In the first phase of the study, half the children receive an oral dose of CBD and half placebo. In the second phase, the groups are switched and the half who originally received CBD receives placebo, while the initial placebo group receives CBD. Investigators are blinded to which children are receiving which treatment until after all of the testing is completed at the end of the study.
For more information about the CMCR, click here.
For additional details about the study please visit ClinicalTrials.gov or submit our Study Interest Survey.
Therapeutic Efficacy of Cannabis and Cannabinoids in Prescription Opioid Abuse and Addiction INVESTIGATOR: Michael Taffe, PhD
STUDY LOCATION: University of California, San Diego
PROJECT TITLE: Therapeutic Efficacy of Cannabis and Cannabinoids in Prescription Opioid Abuse and Addiction
FUNDING SOURCE: Center for Medicinal Cannabis Research
PROJECT TYPE: Pre-Clinical Study
STATUS: Active
ABSTRACT:
The non-medical abuse of opioids is a significant global health problem. In the United States, approximately 2 million people have a prescription opioid-related abuse disorder, which may increase the likelihood of later non-prescription opioid use and prescription opioid-related overdose deaths. Clinical and epidemiological evidence suggest that cannabis may attenuate harms associated with opioid use and that the opioid-sparing effects of cannabinoids may alter the rewarding effects of opioids. Using a new method for delivery of drugs to rats via e-cigarette technology, this study will determine if inhalation of crude cannabis extract, delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) will decrease oxycodone self-administration behavior and attenuate withdrawal mediated effects in opioid-dependent subjects. The goals of this project will be achieved through the following aims: (1) determine the effects of acute or repeated cannabis extract, THC or CBD treatment on prescription oxycodone self-administration behavior and (2) elucidate mechanisms by which cannabis extract, THC or CBD modulate brain stress-reward function associated with opioid intoxication and withdrawal. We hypothesize that cannabis and cannabinoid treatment via inhalation will attenuate oxycodone abuse- and withdrawal-induced behaviors, and that cannabinoids will have neuroprotective effects on stress-reward signaling mechanisms. Overall, this proposal will elucidate the therapeutic effects of cannabis and cannabinoids on the behavioral and molecular outcomes of prescription oxycodone addiction and dependence.
Engaging the endocannabinoid system with cannabidiol to reduce anxiety reactivity INVESTIGATOR: Charles Taylor, PhD
STUDY LOCATION: University of California, San Diego
PROJECT TITLE: Engaging the Endocannabinoid System with Cannabidiol to Reduce Anxiety Reactivity: A Randomized Controlled Trial in Social Anxiety Disorder
FUNDING SOURCE: NIH
PROJECT TYPE: Clinical Study
STATUS: Enrolling
ABSTRACT: Cannabis-based products are commonly used by the public to self-manage symptoms of anxiety; however, people are making decisions about what type of product to use (e.g., CBD, THC), and in what doses, in the absence of rigorous empirical data. Cannabidiol (CBD) is a non-intoxicating phytocannabinoid that has shown promise – based on animal and single dose findings in humans – as a natural therapeutic for anxiety and stress-related disorders. These conditions are common, disabling, and for which first-line pharmacological and psychosocial treatments fail 50% of patients. Although initial evidence suggests that CBD has anxiolytic properties, the dose-dependent biological and behavioral effects have not been characterized in clinically anxious samples. No studies, to our knowledge, have compared different CBD doses within the same clinical sample, nor have putative biological targets (e.g., endocannabinoid function) been measured alongside anxiety reactivity or symptom measures. This limited knowledge has impeded the translation of single dose findings to chronic dosing randomized clinical trials in anxiety populations. The proposed two-phase, milestone-driven project intends to address this gap by advancing knowledge about the mechanisms and therapeutic potential of CBD for anxiety. We will test the causal role of endocannabinoid-mediated anxiety reactivity in reducing clinical symptoms and impairment in patients diagnosed with social anxiety disorder (SAD). The R61 phase project will evaluate the dose-dependent effects of CBD on blood plasma levels of anandamide (an endogenous cannabinoid that has been shown to regulate stress responses; primary biological signature) and anxiety reactivity to a social stress task (secondary target) in a sub-acute (4-day) dosing study (i.e., when steady state CBD levels have been reached). Aim 1 will test the hypothesis that CBD increases anandamide levels and decreases anxiety reactivity compared to placebo. Aim 2 will determine which dose (300 or 900 mg/d) of CBD produces a greater effect on anandamide and anxiety reactivity. If CBD is found to be superior to placebo in elevating plasma anandamide levels and reducing anxiety reactivity, the R33 phase project will attempt to replicate the R61 project findings (Aim 1; sub-acute dosing study) and examine whether changes in anandamide and anxiety responses are associated with clinical improvement (i.e., reduction in anxiety symptoms and impairment; Aim 2) following an 8-week double-blind, randomized, placebo-controlled trial of CBD (dose informed by the R61 project) in subjects diagnosed with SAD. Secondary clinical outcomes will be change in functional interference, and co-occurring symptoms of depression and general anxiety. Positive findings will support a larger confirmatory efficacy trial to further evaluate the therapeutic potential of CBD for anxiety disorders. Regardless of study outcomes, important information will be gained about the role of CBD in modulating endocannabinoid-mediated anxiety outcomes, which will pave the way for future research on cannabinoids and anxiety.
If interested, please fill out this brief pre-screen to determine your initial eligibility! If the pre-screen shows that you are initially eligible for our research study, please be sure to follow the instructions listed to provide your contact information.
For further information call (858) 534-6407 or email [email protected]
Efficacy of inhaled cannabis versus placebo for the acute treatment of migraine INVESTIGATOR: Nathaniel Schuster, MD
STUDY LOCATION: University of California, San Diego
PROJECT TITLE: A Randomized, Double-Blind, Placebo-Controlled Trial of Vaporized Cannabis for the Acute Treatment of Migraine
FUNDING SOURCE: Migraine Research Foundation
PROJECT TYPE: Clinical Study
STATUS: Active
ABSTRACT: This study is funded by the Migraine Research Foundation. People with migraine will treat 4 distinct migraines with vaporized cannabis with either ~0% THC and CBD (placebo), ~5% THC, ~12% CBD, or ~5% THC with ~12% CBD. The purpose is to determine the effect of THC and CBD on acute migraine with regards to pain freedom and pain relief, most bothersome symptom, and on its individual associated features (photophobia, photophobia and nausea).
The Effects of THC on Glucose Metabolism and Endothelial Function in Subjects with Type 2 Diabetes INVESTIGATOR: Jeremy Pettus, MD
STUDY LOCATION: University of California, San Diego
PROJECT TITLE: The Effects of THC on Glucose Metabolism and Endothelial Function in Subjects with Type 2 Diabetes
FUNDING SOURCE: Center for Medicinal Cannabis Research
PROJECT TYPE: Clinical Study
STATUS: Active
ABSTRACT:
Delta-9 tetrahydrocannabinol (THC) use is becoming increasingly common amongst patients with type 2 diabetes (T2D). Indeed, a recent national survey showed a dramatic 340% rise in cannabis use among individuals with T2D. In parallel, the incidence of T2D is increasing at an alarming rate. However, data regarding THC use in T2D are frequently contradictory. For example, epidemiologic data suggest an inverse cannabis-T2D association, however animal studies suggest cannabis increases hyperphagia, obesity, and insulin resistance. Additionally, data on how cannabis affects cardiovascular disease risk is limited with studies either finding a protective or deleterious effect on inflammation, endothelial function (EF), and other markers of CVD risk. Thus, how THC affects glucose metabolism and CVD risk in T2D is not known. We seek to address this gap in knowledge by conducting the first prospective, randomized, placebo-controlled, clinical trial comparing cannabis whole plant material (4% THC) versus placebo cannabis (THC extracted) obtained from the NIDA Drug Supply Program in subjects with T2D.
This study will address two specific aims. Aim 1: Determine the effects of THC on glucose metabolism. We hypothesize that THC will improve insulin sensitivity measured as peripheral glucose disposal during an insulin clamp. Aim 2: Determine the effects of THC on inflammation and EF. We hypothesize that THC impairs EF via proinflammatory mediators. To test our hypothesis, 30 subjects with T2D will be randomized to either THC or placebo, administered twice daily via vaporization (Mighty Medic Vaporizer, Storz-Bickel, Tuttlingen, Germany). After 2 weeks of treatment, subjects will undergo a hyperinsulinemic-euglycemic clamp, OGTT, and indirect calorimetry to quantify insulin sensitivity, insulin secretion, glucose metabolism and energy expenditure respectively (Aim 1). Subjects will also undergo assessments to quantify micro- and macrovascular EF and inflammatory milieu as measured by reactive hyperemia peripheral arterial tonometry, flow mediated dilation, and peripheral blood inflammatory profile respectively. Patients will then crossover into the alternative treatment arm and all procedures will be repeated after 2 weeks. With both cannabis use and the prevalence of T2D rising, it is now a public health imperative to understand how THC affects metabolism and markers of CVD risk. The results of this study will help shape recommendations for THC use in patients with T2D.
Analgesic, appetite-stimulating, and subjective effects of cannabigerol administered alone and in combination with delta-9-tetrahydrocannabinol INVESTIGATOR: Ziva Cooper, PhD
STUDY LOCATION: University of California, Los Angeles
PROJECT TITLE: Analgesic, appetite-stimulating, and subjective effects of cannabigerol administered alone and in combination with delta-9-tetrahydrocannabinol
FUNDING SOURCE: Center for Medicinal Cannabis Research
PROJECT TYPE: Clinical Study
STATUS: Active (Enrolling)
ABSTRACT:
Chronic pain is a significant public health burden for which there are few effective treatments lacking adverse effects that limit their long-term use. Anorexia frequently co-occurs with pain; severity of appetite impairment is positively associated with pain intensity. Delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, holds promise as a therapeutic candidate to treat chronic pain.
THC and has also been established as a therapeutic for anorexia associated with Acquired Immunodeficiency Syndrome (AIDS) and is used to stimulate appetite associated with other disorders. However, THC’s analgesic and orexigenic effects can be accompanied by intoxication, abuse liability, and cognitive disruption limiting its clinical utility. Cannabigerol (CBG) is a minor cannabinoid that, in laboratory animals, lacks the psychoactive side effects of THC. Preclinical studies point to CBG’s potential pain-relieving and appetite stimulating effects but these findings have yet to be translated to humans. It has been hypothesized that minor cannabinoids, like CBG, may interact synergistically with THC to enhance therapeutic outcomes while reducing negative psychoactive effects. Specifically, CBG may increase the analgesic and appetite stimulating effects of low, minimally intoxicating, doses of THC, and/or reduce adverse consequences of higher THC doses. Understanding if CBG has analgesic and appetite-stimulating properties alone or in combination with THC is fundamental to developing novel cannabinoid-based therapeutics for these indications. At a time when pharmacotherapeutic strategies to decrease reliance on opioids for pain relief are desperately needed and novel orexigenic agents are warranted, probing the analgesic and appetite stimulating effects of CBG and its potential THC-sparing effects is of significant interest. The proposed double-blind, placebo-controlled study will be the first to assess the dose-dependent analgesic, appetite-stimulating, and adverse effects of CBG alone and in combination with THC in volunteers. Analysis of plasma THC, THC metabolites, and CBG will determine the degree to which effects observed under CBG-THC dose combinations are due to a pharmacokinetic interaction. The objectives of this study address a central mission of the Center for Medicinal Cannabis Research. Study findings will be essential in understanding the clinical potential of CBG alone and in conjunction with THC for pain management and anorexia.
Cannabidiol for Sedative/Hypnotic-sparing Management of Insomnia in Adults INVESTIGATORS: Mariana Cherner, PhD
STUDY LOCATION: University of California, San Diego
PROJECT TITLE: Cannabidiol for Sedative/Hypnotic-sparing Management of Insomnia in Adults
FUNDING SOURCE: Center for Medicinal Cannabis Research
PROJECT TYPE: Clinical Study
STATUS: Active (Enrolling)
ABSTRACT:
It is estimated that up to a third US adults suffer from sleep problems, which are in turn associated with sub-optimal, and sometimes compromised, daily functioning. Sedative and hypnotic medications constitute the main pharmacologic treatment for insomnia, but they are habit-forming and associated with adverse next-day “hangover” effects, including impaired driving and risk of falls. Sedative/hypnotics are also increasingly being linked to longer-term neurocognitive deficits. Therefore, a substitute medication with low abuse potential and a benign cognitive profile would be highly desirable. As the endocannabinoid system is involved in regulation of circadian rhythm, exogenous cannabinoids may have therapeutic potential in the area of sleep. A few studies not specifically targeting insomnia indicate that CBD use may result in sedation. However, objective scientific evidence is lacking with regard benefits, detrimental effects, or effective dose. We propose a randomized, double-blind placebo-controlled phase II study to examine the noninferiority and efficacious dose range of CBD in managing symptoms of insomnia compared to sedative/hypnotic medication. We will measure sleep outcomes objectively using wrist-worn actigraphy as well as by self-report via real-time ecological momentary assessment and traditional questionnaires. We will also compare objective next-morning neuropsychological performance. Positive study results will provide support for the use of CBD as a potential sedative/hypnotic-sparing treatment for insomnia.
Cannabis Use and the Endocannabinoid System in Bipolar Disorder INVESTIGATORS: William Perry, Ph.D. & Jared Young, Ph.D STUDY LOCATION: University of California, San Diego
PROJECT TITLE: Cannabis Use and the Endocannabinoid System in Bipolar Disorder
PROJECT TYPE: Clinical Study
STATUS: Active
ABSTRACT:
This study will look at the impact of chronic cannabis use as well as the effects of acute administration of the principal constituents of cannabis on cognition and brain levels of endogenous cannabinoids and the neurotransmitter dopamine.
Cannabis use is highly prevalent in people with Bipolar Disorder (BD) and likely results in significant cognitive and behavioral disturbance in a population already vulnerable to cognitive deficits. Parallel studies in rodent models of BD will enhance the understanding of the neurobiology of cannabis use from acute, chronic, and withdrawal perspectives, and may ultimately lead to novel treatment targets.
CMCR Cannabis research centre
The Center for Medicinal Cannabis Research (CMCR) was established at the University of California, San Diego in 2000, thanks to the vision of then Senator John Vasconcellos and the leadership of then-University of California President Richard Atkinson.
CMCR was initially funded with a $3 million annual allocation from the State of California, under the mandate of the California State Legislature. The primary objective was to conduct high-quality scientific studies intended to ascertain the safety and efficacy of cannabis and cannabis compounds for treating medical conditions.
From 2000 to 2010, researchers at CMCR conducted several studies on the potential medical benefits of cannabis. These included investigations into its efficacy in treating neuropathic pain associated with HIV/AIDS, multiple sclerosis, diabetes, and spinal cord injury, in addition to research into cannabis’s potential to alleviate spasticity and other symptoms related to various neurological conditions.
In 2010, the state funding ended, but the CMCR continued its research activities using the remaining balance of the initial state funding, as well as federal grants and other sources of funding. During this period, the CMCR expanded its scope to include research into the potential risks associated with cannabis use, in addition to its potential benefits.
Over the course of its history, the CMCR has made significant contributions to our understanding of the potential therapeutic applications of cannabis. Its research has provided strong evidence for the efficacy of cannabis in treating chronic neuropathic pain and has also shed light on potential adverse effects of long-term cannabis use, such as cognitive impairment and an increased risk of addiction.
In recent years, the CMCR has expanded its research efforts to include studies on the potential therapeutic effects of cannabidiol (CBD), a non-psychoactive compound found in cannabis, as well as the potential benefits of cannabis for treating additional conditions such as autism and post-traumatic stress disorder.
Despite the numerous challenges associated with conducting research on a Schedule I drug, the CMCR has been at the forefront of advancing the science of medicinal cannabis and continues to contribute to our understanding of its potential benefits and risks.
You might be interested in exploring more about the University of California – Center for Medicinal Cannabis Research, which has been a pioneer in scientific exploration and policy research related to the therapeutic benefits and limitations of cannabis and cannabinoids. Speaking of cannabis, you might be interested in learning more about its potential benefits for treating conditions such as autism and post-traumatic stress disorder. To delve deeper into these topics, you can check out the Cannabis and Autism Spectrum articles on Wikipedia.
The cannabis industry has undergone a period of significant transformation over the past decade. As legalization has spread across the United States and other parts of the world, the market for cannabis products has grown rapidly. This growth has been accompanied by changes in the prices and potency of cannabis products.
A comprehensive analysis of data regarding the price and potency of cannabis, specifically between the ten-year span of 2011 to 2021, unearths some fascinating trends and patterns. This period was marked by significant changes in the global cannabis market, influenced by evolving societal attitudes, changes in legal frameworks, as well as the advent of more advanced cultivation and processing techniques.
The price of cannabis resin, a concentrated form of cannabis that contains high levels of THC, exhibited a moderate increase over the stated decade. This is likely due to factors such as increased production costs, changes in supply and demand, as well as the legalization and subsequent regulation of cannabis in various regions. The rise in prices could also be attributed to the enhanced quality and potency of resin products available in the market.
In contrast, the prices of cannabis herbal products, which include buds, leaves, and flowers of the cannabis plant, remained relatively stable throughout the decade. With a more saturated market and diverse product offerings, the pricing for herbal cannabis products has been kept in check. The growth of home-growing options, facilitated by the legalization of cannabis in certain regions, may have also played a role in maintaining price stability.
However, while there were notable differences in the pricing trends of resin and herbal products, the potency of both types of cannabis experienced a substantial surge. Potency, usually measured by the concentration of tetrahydrocannabinol (THC) and cannabidiol (CBD), saw a dramatic increase. It is interesting to note that in some instances, the strength of the cannabis products more than doubled over the ten-year period.
The escalation in potency can be attributed to multiple factors. Advances in cultivation techniques have led to the production of cannabis plants with higher THC and CBD levels. Breeders have been able to develop new strains of cannabis with increased potency by selectively breeding plants with high THC or CBD levels.
Moreover, the growing market competition has spurred cannabis producers to focus on enhancing potency as a unique selling proposition. Also, with more educated and discerning consumers, there has been a noticeable shift towards demand for higher potency products. This consumer preference, combined with advancements in cultivation, likely drove the significant increase in the potency of both cannabis resin and herbal products.
In conclusion, the last decade has witnessed a moderate increase in the price of cannabis resin, stability in the price of cannabis herbal products, and a significant rise in the potency of both product types. These trends not only reflect changes in the cannabis market but also represent wider societal and legal shifts towards the acceptance and regulation of cannabis. As we move forward, it will be interesting to see how these trends evolve in the face of continued developments in the global cannabis industry.
The amplified potency of cannabis products has been a significant trend in recent years, a phenomenon that can be attributed to several factors. The key among these factors are advancements in cultivation and extraction techniques, both of which have dramatically increased the concentration of Tetrahydrocannabinol (THC), the psychoactive compound in cannabis.
Firstly, the arena of cannabis cultivation has been revolutionized by leaps in technological and horticultural innovations. Growers and cultivators, with their increased knowledge and sophisticated techniques, have significantly improved their ability to produce cannabis plants with higher potency. This has not been the result of a whimsical trial and error process but a structured, scientific approach based on a deep understanding of plant genetics and advanced cultivation methodologies.
The cultivation techniques have drastically evolved over the years, with growers now having a better understanding of the optimal environmental conditions for enhancing the yield and potency of cannabis plants. These conditions include everything from the appropriate levels of light and heat to the right nutrient mix and watering schedules. By meticulously controlling these variables and leveraging the right genetic strains of cannabis, growers have been able to coax their plants into producing higher levels of THC. This has resulted in cannabis products with significantly increased potency.
In addition to the strides made in cultivation, the development of new and more efficient extraction methods has further contributed to the increased potency of cannabis products. Extraction techniques have evolved, enabling the production of concentrated forms of cannabis that are far more potent than the traditional cannabis flower. Cannabis concentrates, such as shatter and wax, have emerged as prime examples of this trend.
Shatter and wax are highly concentrated cannabis extracts that offer a more potent and potentially more effective alternative for medicinal and recreational users alike. These products are created by using solvents like butane or carbon dioxide to extract the psychoactive compounds from the cannabis plant. The resulting product is a concentrated form of cannabis that contains a much higher proportion of THC than traditional cannabis flower.
Moreover, these extraction techniques not only increase the potency but also allow for the removal of harmful impurities and unwanted plant matter. This results in a purer, more potent form of cannabis that delivers a more intense effect and arguably, a better user experience.
In conclusion, the rise in the potency of cannabis products is a complex phenomenon, born out of advancements in both the cultivation and extraction of cannabis. Growers, through their enlightened understanding of plant genetics and optimal cultivation conditions, have been able to grow cannabis plants with higher THC levels. Concurrently, new extraction methods have resulted in the production of concentrated cannabis products, such as shatter and wax, that deliver a far more potent punch than traditional cannabis flower, setting a new standard in the cannabis industry.
The ongoing surge in the strength of cannabis products has caused a significant rise in apprehensions regarding the potential for adverse health effects. This increase in potency is not merely a minor increment but a substantial magnification of the drug’s psychoactive component, leading to a consequent escalation in its impact on human health. The problem is acute, and it brings under the spotlight the alarming possibility of inflicting considerable harm on users, particularly those who are young or inexperienced.
High-potency cannabis, characterized by an elevated concentration of the psychoactive compound, THC (tetrahydrocannabinol), can indeed heighten the likelihood of developing an addiction. It is important to note that the more potent the cannabis, the more likely it is to alter the brain’s reward system, compelling the user to seek out the drug compulsively, despite the negative repercussions. This dependence can spiral into a serious addiction, causing users to prioritize the drug over essential life activities, thus negatively impacting their quality of life.
Furthermore, the use of potent cannabis is not only associated with the risk of addiction but it has also been linked to an increased risk of psychosis among consumers, notably young people. The relationship between cannabis use and psychosis, a severe mental disorder characterized by a disconnection from reality, has been extensively researched and well documented. Young individuals, whose brains are still developing, are particularly vulnerable to the psychoactive effects of cannabis. The high potency of today’s cannabis products can trigger more intense reactions, leading to confusion, hallucinations, and potentially, the onset of psychotic disorders.
In addition to these concerns, the ingestion of high-potency cannabis can amplify the risk of impaired driving and a host of other accidents. THC affects areas of the brain that control body movements, balance, coordination, memory, and judgment – abilities that are essential for safe driving. When someone drives under the influence of cannabis, they are more likely to be involved in an accident because their reaction times and coordination may be impaired. The risks extend beyond driving, as the use of potent cannabis can also lead to mishaps in day-to-day activities, potentially causing physical harm or even fatalities.
In summary, the rise in the potency of cannabis products is a public health issue that needs to be addressed urgently. The increased likelihood of developing an addiction, the potential onset of psychosis, particularly among young people, and the heightened risk of impaired driving and other accidents, are all significant concerns that society must face. As the popularity of these potent products continues to grow, it becomes even more critical to spread awareness about their potential risks and promote regulatory measures to ensure public safety.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2021). Cannabis price and potency in the European Union (updated June 2021). Retrieved from https://pubmed.ncbi.nlm.nih.gov/30597667/
United Nations Office on Drugs and Crime (UNODC). (2021). World Drug Report 2021. Retrieved from https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html
National Institute on Drug Abuse (NIDA). (2022). Marijuana Research Report. Retrieved from https://nida.nih.gov/research-topics/marijuana/nih-research-cannabis-cannabinoids
The potency of cannabis has increased significantly over the past few decades. This is due to a number of factors, including:
Advances in cultivation techniques: Growers have developed new methods for breeding and cultivating cannabis plants that produce higher levels of THC, the psychoactive compound in cannabis. For example, growers can use selective breeding to create plants with desired genetic traits, such as high THC content. They can also use techniques such as hydroponics and aeroponics to provide plants with optimal growing conditions.
Development of new extraction methods: New extraction methods have been developed that can be used to create concentrated forms of cannabis, such as shatter, wax, and dabs. These concentrates can have THC levels of 90% or higher.
Consumer demand for high-potency cannabis: Consumers are increasingly demanding high-potency cannabis products. This is likely due to a number of factors, such as the desire for a more intense experience and the belief that high-potency cannabis is more effective for medical purposes.
As a result of these factors, the average THC content of cannabis has increased significantly over the past few decades. For example, in the 1970s, the average THC content of cannabis was around 3%. Today, the average THC content of cannabis is around 15%. In some cases, THC levels can be as high as 30% or more.
The increase in the potency of cannabis has raised concerns about the potential for negative health effects. High-potency cannabis can be more likely to lead to addiction and psychosis, particularly among young people. Additionally, the use of high-potency cannabis can increase the risk of impaired driving and other accidents.
If you are concerned about the potential risks of high-potency cannabis, it is important to talk to your doctor. They can help you understand the risks and benefits of cannabis use and can provide guidance on how to use cannabis safely.
The new systematic review from Kat Petrilli and Tom Freeman (Psychology) is published in The Lancet Psychiatry. Image credit: AdobeStock.
As the strength or potency of cannabis products has increased internationally over the years, so have rates of people being treated for cannabis addiction, say the authors of a new study.
A team of researchers from the Addiction and Mental Health Group at the noted University of Bath in the United Kingdom embarked on an enlightening journey to delve into the intricate relationship between different types of cannabis usage and the consequential effects on mental health and addiction. The team’s dedication to their work is evident in the methodical and comprehensive analysis they have conducted.
The University of Bath has a long-standing reputation as a reputable institution, with its Addiction and Mental Health Group renowned for their rigorous research on substance abuse and its psychological implications. In this particular project, they sought to explore the hidden correlations between various types of cannabis consumption and their potential harm to mental health.
The researchers were not just probing the surface; they were making a systematic dissection of the available data to uncover new insights. What set this study apart is the sheer scale of the analysis, where the research cross-examined a host of studies from around the world, amassing to a total of 20 independent papers. These studies are not recent but span over several years, thereby providing a more comprehensive and holistic viewpoint.
What was even more impressive was the size of the sample they were dealing with. The researchers examined data from almost 120,000 individuals, an impressive number that significantly boosts the robustness and validity of their findings. This diverse base allowed them to examine a wide array of cannabis users, in terms of age, gender, geographical locations, and cultural backgrounds, thus providing a more in-depth understanding of the issues at hand.
The researchers’ meticulous work has resulted in an intricate tapestry that weaves together various threads of information on the complex relationship between cannabis use and mental health issues. It sheds light on the potential risks and repercussions of using different types of cannabis, taking into account factors such as potency and frequency of usage. Their findings are expected to be instrumental in influencing policies related to cannabis consumption and mental health care, potentially paving the way for improved treatments and preventive measures.
The team’s work is an exemplification of the impact that thorough, systematic research can have in demystifying complex issues related to mental health and addiction. They provide a beacon of knowledge in an area that’s often shrouded in misconception and stigma.
In conclusion, the research conducted by the Addiction and Mental Health Group at the University of Bath is a testament to the power of rigorous and systematic scientific investigation. By peeling back the layers of understanding on a complex issue like cannabis use and its impact on mental health, they are helping to pave the way for more informed choices, better policies, and improved health outcomes.
After alcohol and nicotine, cannabis is the most widely used drug globally. Latest estimates from the UK suggest that over the last year around one in five 16-24 year olds had used cannabis.
Cannabis potency refers to the concentration of tetrahydrocannabinol (THC) in cannabis – the key psychoactive drug it contains. Recent studies from the same team at Bath have found that the concentration of THC in cannabis has increased significantly over time meaning that cannabis used today is typically much stronger than previously.
A groundbreaking research recently published in the esteemed scientific journal, The Lancet Psychiatry, has put forth significant evidence indicating that the use of high-potency cannabis has potential to lead to more cases of addiction compared to the use of low potency counterparts. The study also suggests a strong correlation between the prolonged use of high-potency cannabis and an increased likelihood of experiencing psychotic disorders, such as schizophrenia.
The study, a thorough examination of cannabis use and its potential risks, has been hailed as a significant contribution to the ongoing debate surrounding cannabis legalization and regulation. The findings offer considerable insights into the differentiated risks associated with cannabis usage based on its potency. High-potency cannabis, often referred to as skunk due to its strong smell, contains a higher concentration of the psychoactive substance tetrahydrocannabinol (THC). This is the compound responsible for the ‘high’ experienced by users and, in stronger concentrations, has now been linked to a significant increase in the risk of addiction.
The research also shed light on the potential psychological consequences of frequent high-potency cannabis use, showing a heightened risk of developing serious mental health disorders, such as schizophrenia. Schizophrenia is a severe, long-term mental health condition that can cause a range of different psychological symptoms, including hallucinations, delusions, muddled thoughts, and changes in behaviour. The study’s findings reveal a concerning association between high-potency cannabis use and the onset of such symptoms, propelling the need for further scientific exploration in this domain.
It’s crucial to mention that the study doesn’t definitively establish that high-potency cannabis causes addiction or mental health disorders, but rather, it highlights a strong correlation. The researchers have urged caution, underscoring the urgency of comprehensive regulatory measures to control the availability and use of high-potency cannabis, while also emphasizing the need for public education about the potential risks associated with its use.
The revelations of this study have major implications for public health policy, as well as for individuals who use cannabis, either recreationally or medicinally. For policymakers, these findings necessitate a review of current laws and regulations surrounding cannabis, particularly those pertaining to the potency of cannabis products available on the market. For individual users, this study underscores the need for greater awareness of the potential risks associated with high-potency cannabis use, from addiction to serious mental health disorders.
In conclusion, the new study serves as a stark reminder that while cannabis can indeed have therapeutic applications, it’s far from benign. The researchers contend that there’s a pressing need for further studies to fully understand the long-term effects of high-potency cannabis use on mental health, with an aim to inform future legislation and public health initiatives. Until then, users should exercise caution and be aware of the potential risks associated with high-potency cannabis.
These findings may help to explain why more people have received treatment for cannabis problems over recent years. Data from the European Monitoring Centre for Drugs and Drug Addiction show a 76% increase in people entering treatment for cannabis addiction in the past decade.
Based on these new results, the authors argue that public health guidelines and policies to help make cannabis use safer should be encouraged.
The lead author of a groundbreaking new study, Kat Petrilli, from the well-respected University of Bath’s Department of Psychology, has recently shared some eye-opening insights. Petrilli’s research offers comprehensive findings, potentially reshaping our understanding of cannabis use and its associated risks.
Petrilli’s study deeply delves into the effects of cannabis potency on users. Cannabis, a highly debated topic globally, has a wide range of potencies, which is a metric often overlooked in discussions about its impacts on health. However, Petrilli’s research has shed light on this significant aspect of cannabis use, bringing to the forefront the potential risks associated with higher potency variants of the drug.
At the core of Petrilli’s enlightening research is a systematic review of existing literature. Through careful examination of numerous studies, she has been able to identify a worrying pattern. People who consume higher potency cannabis appear to be at a greater risk of addiction as well as psychosis when compared to their counterparts who use cannabis products of lower potencies. This finding is a significant contribution to the pool of knowledge about cannabis, its variants, and the potential risks associated with its use.
In the words of Petrilli, “Our systematic review found that people who use higher potency cannabis could be at increased risks of addiction as well as psychosis when compared to people who use cannabis products with lower potencies.” This statement, succinctly summarizing the results of the comprehensive review, serves as a stark warning about the implications of using high-potency cannabis.
Given the ongoing debates about the legalization of cannabis in numerous countries, these findings are especially pertinent. The research conducted by Petrilli and her team at the University of Bath’s Department of Psychology underscores the importance of considering potency when discussing potential risks and regulations around cannabis use.
This study also raises essential questions about how we understand cannabis use. If higher potency cannabis increases the risk of addiction and psychosis, what does this mean for the users and the societies in which they live? What should the response be from policymakers, healthcare providers, and communities? Petrilli’s research does not just contribute to academic discourse but calls for practical applications and responses to manage these identified risks effectively.
In summary, the research led by Kat Petrilli has brought forth the potential dangers of high-potency cannabis, calling for a more nuanced approach in dealing with this controversial substance. There’s much more to cannabis than its controversial status, and studies like Petrilli’s are instrumental in helping us navigate its complexities. As we continue to debate and explore the issue of cannabis use, insights such as these will prove invaluable in shaping our understanding and response to this multi-faceted phenomenon.
“These results are important in the context of harm reduction which aims to minimise the negative consequences associated with drug use. While the safest level of use for cannabis is of course ‘no use’, it is important to acknowledge that a significant number of people across the world use cannabis regularly and to ensure they can make informed decisions that could reduce any possible harms associated with it.”
The authors point out that strategies to make cannabis use safer could inform how the drug is regulated in the UK and internationally. Recreational cannabis use remains illegal in the UK, but cannabis products are now legally sold for recreational use in Canada, Uruguay, and parts of the USA.
Several other countries appear set to follow this trend, including Germany. In the UK, the Liberal Democrats have argued that a legal regulated market could make cannabis use safer by enforcing a limit on the potency of cannabis products, and investing the revenue and savings from this into education and treatment for cannabis problems.
The senior author of the study, Dr Tom Freeman, whose research work can be found on Bath University’s research portal, has elucidated his team’s findings in his recent interview, shedding light on the potential of mitigating harm associated with cannabis usage.
Dr Freeman begins by highlighting their core discovery: “Our findings suggest that people who use cannabis could reduce their risk of harm by using lower potency products.” This assertion is based on the comprehensive research conducted by Dr Freeman and his team, which involved the study of various cannabis users and the effects of the drug on them over a substantial duration. The research team meticulously observed and recorded the impacts of different cannabis potencies on the users, ultimately establishing a correlation between the product’s strength and the consequent harm it could inflict.
Their findings indicated that the negative effects were considerably lower among users who opted for products with less potent effects. These effects range from mental health issues like anxiety and depression to physical problems such as respiratory complications and dependency issues. Lower potency cannabis products seemed to present less risk of these potential hazards, thus lending credence to Dr Freeman’s assertion.
Delving deeper into the implications of their findings, Dr Freeman emphasizes the role of consumer education and product transparency in minimizing cannabis-related harm. He states, “In places where cannabis is legally sold, providing consumers with accurate information on product content and access to lower potency products could help people to use cannabis more safely.”
Dr Freeman suggests that disseminating precise and detailed product contents to consumers can help them make informed decisions regarding their cannabis usage. Having access to thorough information about the potency of the product they are consuming allows users to choose lower strength variants, thereby reducing the potential risk associated with their cannabis usage.
Moreover, ensuring easy and legal access to lower potency cannabis products can play a vital role in promoting safe usage. Dr Freeman believes that legal establishments selling cannabis should not only stock these less potent options but also actively promote them as a safer alternative to their higher strength counterparts.
In essence, Dr Tom Freeman’s research stresses the importance of potency in determining the risk levels of cannabis usage. His findings advocate for a more educated and cautious approach towards the consumption of cannabis, emphasizing the need for accurate product content information and access to lower potency products. The adoption of these measures could potentially redefine the way people use cannabis, shifting the focus towards safety and harm reduction.
Despite anecdotal evidence of links between cannabis and anxiety and depression, the authors note that the links between cannabis potency and other mental health problems are unclear.
This research was funded by the Economic and Social Research Council.
https://www.emcdda.europa.eu/publications/european-drug-report/2023_en Cannabis continues to reign unchallenged as the most widely used illegal drug in the European arena, a fact corroborated by the data made available in the European Drug Report 2023. This page offers an elaborate, comprehensive, and up-to-date analysis of the cannabis situation spread across European territories. It provides an all-encompassing view of the integral facets of cannabis consumption, such as its prevalence, the demand for treatment, seizure rates, pricing and purity levels, associated harms, and much more. This insight into Europe’s cannabis situation is a part of the European Monitoring Centre for Drugs and Drug Addiction’s (EMCDDA) broader annual report on the drug scene in Europe. The European Drug Report 2023 thoroughly scrutinizes the overall narcotic landscape, laying particular emphasis on the most commonly consumed illicit drug – cannabis. As of the most recent update on the 16th of June, 2023, the report conclusively states that cannabis remains the predominant illicit substance in Europe. This fact is based on a wide array of metrics, ranging from user prevalence to health impacts, to law enforcement seizures. A critical component of the report involves an examination of the prevalence of cannabis use across Europe. To this end, it studies the extent of cannabis consumption across different age groups and demographics, offering an in-depth look into the societal reach of this drug. Moreover, the report also investigates the demand for treatment resulting from cannabis use. This analysis provides crucial insights into the health impacts and the degree of addiction caused by the substance, thereby revealing the drug’s influence on the healthcare system. Another pertinent aspect covered in the report is the data regarding seizures of cannabis. Law enforcement actions such as these reflect the magnitude of illegal cannabis trafficking and trade within European borders. This, in turn, provides us with a clearer picture of the illicit drug market’s size and operation. Additionally, the analysis delves into the price and purity of cannabis. By studying these factors, the report enables a better understanding of the drug’s market dynamics, including supply, demand, and consumer behavior. The report also addresses the harms caused by cannabis. These include both direct harms, such as health issues, and indirect harms, such as societal and economic consequences. This comprehensive examination of cannabis-related harms provides a multi-dimensional perspective on the drug’s impact on individuals and society at large. In conclusion, this page forms an integral part of the EMCDDA’s annual overview, the European Drug Report 2023. It provides a holistic and in-depth view of the cannabis situation in Europe, thereby contributing significantly to our understanding of the broader drug scenario in the region. Stay tuned for future updates and continuous monitoring of the evolving cannabis landscape in Europe. Last updated: 16 June 2023
Unraveling the Public Health Consequences of Ubiquitous Cannabis Products
Cannabis holds a prominent place as the most frequently consumed illicit drug across Europe. When scrutinized on a national level, surveys on cannabis use suggest that approximately 8% of European adults, which equates to an estimated 22.6 million individuals aged between 15 and 64, have used cannabis in the last year. This information is, however, subject to change due to the diverse levels and patterns of cannabis use highlighted in recent national data (refer to the Prevalence of Cannabis Use in Europe dashboard for more information).
Within the European Union, about 1.3% of the adult population, or approximately 3.7 million individuals, are believed to be daily or nearly daily users of cannabis. This segment of the population is more likely to encounter issues related to cannabis use. Despite the frequency of cannabis consumption within this group, there is still a lack of comprehensive understanding of the problems that these individuals face due to cannabis use. Furthermore, the referral pathways and treatment options available to those grappling with cannabis-related problems need to be explored more thoroughly.
Cannabis is associated with nearly one-third of all drug treatment admissions in Europe, a statistic that is challenging to interpret due to the wide variety of interventions offered to cannabis users. Some of these interventions may be directive referrals emanating from the criminal justice system, underlining the complex interplay between illicit substance use and legal implications.
A recent review conducted by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) identified an uptick in the availability of psychosocial treatments, such as cognitive behavioural therapies, for individuals experiencing problems related to cannabis use. These interventions are sometimes delivered via telemedicine or digital applications, signalling a shift towards more accessible and innovative treatment options.
When examining those who have entered specialist drug treatment for the first time, the proportion of people who cited cannabis as their primary problematic drug remained below the levels reported pre-COVID-19 pandemic across most EU Member States in 2021 (refer to the Users Entering Treatment for Cannabis infographic for more information). Overall, the number of individuals reported as entering treatment for cannabis-related problems maintained a relatively steady pace up until 2019. However, a decline was noted during the global pandemic, and the numbers have not rebounded to pre-pandemic levels. Still, the interpretation of these trends is complicated due to data limitations and inconsistencies. Comprehensive and reliable data is integral to fully understand the scope of cannabis use and the associated problems, which, in turn, is critical for the development and implementation of effective public health policies and practices.
In the year 2021, both the quantities of cannabis resin and herbal cannabis that were seized hit their highest point in a span of ten years. This marked increase points to the significant availability of this particular drug, a trend that is clearly depicted by the Cannabis market infographic provided below. The data suggests a clear growth in the cannabis market, both in terms of production and consumption.
Spain emerges as a key player in this scenario, accounting for a massive 66% of the total number of cannabis seizures within the European Union. To add to this, Spain also boasts a whopping 74% of all the EU seizures of cannabis plants when reported by weight. This data underlines the influential role of Spain in the cannabis market, not just as a transit country facilitating cannabis trafficking, but also as a significant production area.
However, it is imperative to note that notable cannabis production is not limited to Spain alone. On the contrary, it is a phenomenon that is dispersed across various regions within the European Union. The geographical distribution of cannabis production within the EU is vast and varied, contributing significantly to the overall availability of the drug.
The quantities of cannabis resin seized in Europe exceeded that of herbal cannabis. This discrepancy is thought to reflect the heightened vulnerability of cannabis resin to interdiction measures employed in cross-border trafficking, as opposed to the actual availability or usage of the drug. It does not necessarily imply a higher demand or consumption of cannabis resin. Herbal cannabis, in fact, appears to be the most commonly available form of the drug in a majority of countries.
The diversity of cannabis products available in Europe is on the rise. This is observed not merely in the illicit drug market but also in consumer markets, which are now seeing the advent of products containing minimal levels of Tetrahydrocannabinol or THC, the primary psychoactive component of cannabis. In addition to THC, these new products are also known to contain other cannabinoids, expanding the range and variety of cannabis-derived products available to consumers.
The variety and availability of these products are indicators of the changing dynamics of both the illicit drug market and the legal consumer market. The increasing diversity of cannabis products perhaps mirrors the changing attitudes and regulations surrounding cannabis use across Europe. Therefore, it would seem that the cannabis market in Europe is not just growing, but also evolving to accommodate new forms and types of products, a trend that is likely to continue in the years to come.
substances derived from the cannabis plant such as CBD.
In the realm of the illicit drug market, one of the most significant concerns is the availability of extremely potent extracts and edibles. These substances, owing to their considerably high potency, have been directly associated with incidents of acute toxicity. Such cases frequently present themselves in hospital emergency departments, adding to the already overwhelming load of medical professionals. These incidents underscore the potential harm brought about by these substances, representing a public health concern that needs immediate attention.
The manifold issues surrounding the illicit drug market do not end with the availability of high-potency extracts and edibles. Another alarming issue lies in the possibility of adulteration in products marketed as natural cannabis. There are growing concerns that these so-called natural cannabis products may, in reality, be adulterated with powerful synthetic cannabinoids. Synthetic cannabinoids are created in laboratories and designed to mimic the effects of naturally occurring cannabinoids, but they can be far more potent and carry significant health risks. The potential for such adulteration not only misleads consumers about what they are ingesting but also poses a significant health risk due to the unpredictable effects of these synthetic substances.
In recent times, the semi-synthetic cannabinoid hexahydrocannabinol (HHC) has emerged on the market. It has become commercially marketed in several EU Member States and is being sold as a ‘legal’ alternative to cannabis. The emergence of such substances adds another layer of complexity to the already challenging task of regulating the drug market. While the ‘legal’ label may make HHC seem less harmful or risky, the fact is that its effects and potential risks remain largely unknown. The lack of research and understanding about these new substances makes it impossible for users to make informed decisions about their use.
Moreover, the proliferation of such ‘legal’ alternatives to cannabis augments the regulatory challenges in this area. The task of regulating the market becomes even more complicated when these new substances, like HHC, enter the fray. While they might be marketed and sold as legal alternatives, their actual impact on health, both in the short and long term, remains largely unknown. This uncertainty further complicates the task of policy-making and law enforcement, as regulators grapple with the need to protect public health while also addressing the legal ambiguities surrounding these substances.
In conclusion, the illicit drug market presents a multitude of challenges, from the availability of highly potent substances and the potential adulteration of supposedly natural products to the emergence of new, semi-synthetic substances like HHC. Each issue adds to the difficult task of regulation, requiring a robust and well-informed approach to ensure public health is adequately protected.
Prevalence and Patterns of Cannabis Use When considering the information available regarding the prevalence and patterns of cannabis use, the data shows that last year, the estimated usage of cannabis in the European Union population, specifically those aged between 15 and 34, was at 15.1% or roughly 15.3 million individuals. As per the patterns observed, it was revealed that males are typically twice as likely to report using cannabis compared to their female counterparts. This gender difference in cannabis use prevalence has been a consistent pattern observed over the years, highlighting the different societal and cultural norms that influence drug use behavior among males and females. Digging deeper into age-based statistics, it was estimated that 18.2%, or approximately 8.6 million out of the 15 to 24-year-old demographic, had used cannabis over the course of the last year. Further, 9.6% or around 4.5 million individuals from this age group had utilized the drug within the past month. Such data is crucial for understanding emerging patterns of drug use and devising appropriate public health responses. Simultaneously, it was estimated that about 1.3%, or around 3.7 million among adults aged between 15 to 64, are daily or nearly daily cannabis users. This implies that these individuals have used the drug on 20 days or more in the last month. Among the younger demographic of 15- to 34-year-olds, this estimate was slightly higher at 2.1 %, which translates to approximately 2.1 million users. The majority of these frequent cannabis users are male (approximately three-quarters) and most of them (57%) are under the age of 35.
Trends in National Level Cannabis Use When considering cannabis use at the national level, the trends appear to be mixed. Of the countries that have conducted surveys since 2020 and have reported their confidence intervals, three countries reported higher estimates, three reported stable figures, and six reported a decrease compared to their previous comparable survey. This mixed trend underscores the complexity of drug use patterns and highlights the need for country-specific strategies to address the issue. The 2021 European Web Survey on Drugs made some interesting revelations about the different forms of cannabis usage. It found that herbal cannabis was the most popular form of the drug, used by a whopping 95% of respondents who used cannabis in the last 12 months. This is contrasted with 32% who reported using resin, 25% for those who consumed edibles, and 17% for those who used extracts. This data provides valuable insights into the diverse forms and methods of cannabis use, which can guide law enforcement agencies and health professionals in their efforts to address the associated challenges.
Cannabis in Europe
In 2021, EU Member States reported 202 000 seizures of cannabis resin amounting to 816 tonnes (588 tonnes in 2020) and 240 000 seizures of herbal cannabis amounting to 256 tonnes (157 tonnes in 2020). In addition, Türkiye reported 9 800 seizures of cannabis resin amounting to 33 tonnes and 52 500 seizures of herbal cannabis amounting to 31 tonnes.
Approximately 566 000 cannabis use or possession offences were reported in the European Union in 2021 (555 000 in 2020), alongside 100 000 supply offences (99 000 in 2020).
In 2021, the average THC content of cannabis resin in the European Union was 20 %, more than twice that of herbal cannabis, at 9.5 %. However, samples of both forms of the drug can vary considerably.
Cannabis cosmetics are a unique category of beauty products that specifically incorporate cannabis or its derived ingredients into their formulations. These ingredients include but are not limited to Cannabidiol (CBD), Cannabigerol (CBG), Cannabichromene (CBC), Cannabidivarin (CBDV), and Tetrahydrocannabivarin (THCV). These components are extracted from the cannabis plant itself and are then infused into a diverse range of cosmetic products, from facial creams and serums to lip balms and body lotions.
The reason behind the increasing popularity of these cannabis cosmetics is the alleged plethora of benefits they present for the skin. It’s important to note that while the cosmetic industry’s claims about these benefits are based on some research, it’s still a relatively new field, and more extensive studies would further substantiate these benefits.
One of the most frequently highlighted benefits of these cannabis-infused cosmetics is their anti-inflammatory properties. The presence of CBD, in particular, is thought to help reduce inflammation and redness on the skin. This can prove especially beneficial for individuals who experience skin conditions like rosacea, psoriasis, or eczema, where inflammation is a prevalent issue. The anti-inflammatory nature of these products can help to calm the skin and reduce the visible signs of such conditions.
In conjunction with their anti-inflammatory effects, cannabis cosmetics are also touted for their anti-aging properties. Some studies suggest that the antioxidants present in cannabis, particularly in CBD, can help counteract the damaging effects of free radicals in the skin. This, in turn, can help to reduce the appearance of fine lines, wrinkles, and other signs of skin aging, making the skin look healthier and more youthful.
Additionally, cannabis cosmetics are often praised for their moisturizing capabilities. Products containing cannabis or cannabis-derived ingredients can be deeply hydrating, providing the skin with the essential moisture it craves. This can lead to the skin feeling soft, supple, and well-nourished. As such, these products are often recommended for individuals with dry skin or those living in harsh or dry climates.
Finally, these cosmetics are believed to have soothing effects on the skin. The calming properties of CBD and other cannabis-derived ingredients can help to alleviate skin irritations, offering a sense of relief to those with sensitive skin. Users often report a soothing sensation upon application, followed by a significant reduction in skin discomfort.
Overall, while cannabis cosmetics are still a growing trend in the beauty industry, they offer a host of potential benefits for skin health. Their anti-inflammatory, anti-aging, moisturizing, and soothing properties make them a promising addition to any skincare routine. However, it’s always advisable for potential users to conduct their research and, if possible, consult with a skincare professional before incorporating these products into their regimen. This ensures not only the suitability of the product for their specific skin needs but also that they can make the most of what these innovative, cannabis-infused cosmetics have to offer.
However, the legal status of cannabis cosmetics in the USA is not very clear, as different states have different laws and regulations regarding cannabis and its derivatives. The FDA, which is the federal agency responsible for overseeing cosmetics, has not approved any cannabis or cannabis-derived ingredients for cosmetic use, except for hemp seed oil and hemp seed protein. The FDA also does not require pre-market approval for cosmetic products or ingredients, unless they are color additives or prohibited substances.
Therefore, cannabis cosmetics are not illegal in the USA, but they are not officially regulated by the FDA either. This means that manufacturers and sellers of cannabis cosmetics have to comply with other general requirements and regulations for cosmetics, such as safety, labeling, and marketing. They also have to avoid making any medical claims about their products, as that would classify them as drugs and subject them to stricter regulations.
Some companies have taken their own initiatives to set standards for cannabis cosmetics in the USA. For example, Sephora, a giant beauty retailer based in France, has created a CBD standard that requires its products to contain full-spectrum or broad-spectrum CBD from US-grown hemp, have a certificate of analysis from a third-party lab, and be free of harmful substancesAd1. Sephora also offers a range of cannabis cosmetic products from various brands on its website2.
Seventh Sense: Founded on the principle of harnessing the power of nature, Seventh Sense has emerged as a brand that offers an extensive range of CBD-infused products, specifically designed to nurture both your body and mind. The brand prides itself on its premium collection, ranging from soothing creams and aromatic oils to invigorating scrubs, calming bath bombs, and nourishing lip balms — all infused with high-quality CBD to provide an unparalleled wellness experience.
One aspect that distinguishes Seventh Sense’s products is their meticulously crafted formulation, which includes a concentration of CBD. Recognized for its therapeutic properties, CBD has been known to promote relaxation, alleviate anxiety, and even relieve muscle pains. By incorporating this natural compound into their products, Seventh Sense aims to offer a wellness solution that harmoniously balances both physical relaxation and mental tranquility.
Another focal point of Seventh Sense’s product line is their creams. Crafted with high-quality ingredients, they are designed to hydrate, nourish, and rejuvenate the skin. These CBD-infused creams absorb quickly, leaving the skin feeling supple and refreshed without a greasy residue.
Next in their product line are the aromatic oils. Perfect for a soothing massage or a moment of relaxation, these oils come with the added benefits of CBD. Whether it’s their lavender-infused oil for a calming effect or the eucalyptus one for a revitalizing experience, Seventh Sense’s oils are designed to cater to different needs and preferences.
Seventh Sense’s scrubs are another testament to their commitment to quality and wellness. These CBD-infused scrubs gently exfoliate the skin, removing dead skin cells and leaving the skin with a healthy glow.
The brand also offers bath bombs, which are a perfect addition to a relaxing bath routine. Infused with CBD and natural fragrances, these bath bombs dissolve in the water, releasing soothing scents and creating a luxurious bathing experience.
Lastly, for those who seek lip care, Seventh Sense’s CBD-infused lip balms are a delight. They are formulated to moisturize the lips, leaving them soft and smooth. Available in multiple flavors, these lip balms not only offer the benefits of CBD but also provide a pleasant taste.
Seventh Sense’s products are widely recognized for their high-quality ingredients and natural fragrances. By combining nature’s best in their formulations, the brand ensures that their products not only smell divine but also promote overall wellness. With Seventh Sense, customers can access a diverse range of products that offer a natural, holistic approach to personal care and wellness. Infused with the benefits of CBD, their products offer an experience that is truly unique and profoundly soothing.
Prima is a health and wellness brand that has carved a niche for itself in the beauty market by combining the most advanced techniques in clean technology with CBD and botanical extracts. This unique fusion harnesses the powerful properties of CBD, a compound derived from hemp, and blends it with the goodness of natural botanicals, creating a range of products that are marketed as beneficial for both wellness and beauty. To put it simply, they are pioneers in providing CBD-infused wellness and beauty solutions that are paving the way for a more holistic approach to self-care.
Prima’s extensive line of products caters to a diverse range of beauty and wellness needs. This includes a range of creams that have been meticulously formulated to nourish the skin and enhance its natural glow. Their serums, another key product in their lineup, are designed to target specific skin concerns and deliver intensive treatment. Prima also offers balms that can provide soothing and rejuvenating effects, making them ideal for users who have sensitive or irritable skin.
Furthermore, Prima’s range isn’t restricted to topical applications alone. They also offer capsules and powders that complement their line of skincare products. The capsules are designed for those who prefer to incorporate the benefits of CBD and botanicals into their daily diet, while the powders can be easily mixed into your favorite beverages, providing a convenient and tasty way to reap the benefits of these potent ingredients.
What sets Prima apart from other brands in the market is their commitment to sustainability and clean, transparent practices. They are proud to carry the certification from the Environmental Working Group (EWG), a respected non-profit organization dedicated to protecting human health and the environment. Their certification as a clean and sustainable brand is a testament to their dedication to producing products that are not just beneficial for the users, but also for the planet.
This recognition from the EWG is no small accomplishment. It means Prima’s products are free from harmful chemicals and toxins, and that they are produced using sustainable methods that minimize environmental impact. The certification also demonstrates that Prima is committed to transparency, disclosing all their ingredients and production processes, so that consumers can make informed choices about what they put on their skin.
In essence, Prima is revolutionizing the wellness and beauty industry by integrating CBD and botanicals with clean technology. Their range of creams, serums, balms, capsules, and powders are crafted to cater to a variety of needs, while their commitment to clean, sustainable practices sets them apart as a brand that truly cares about the well-being of their consumers and the environment. This makes Prima a preferred choice among consumers seeking natural, effective, and environmentally responsible wellness and beauty solutions.
Flora + Bast: This innovative skincare brand is committed to the creation of age-adapting skincare solutions. With every carefully crafted product, Flora + Bast aims to address skin needs that change as we age, offering customers the promise of rejuvenated, fresh, and youthful skin.
The cornerstone of their unique product line is the incorporation of CBD—Cannabidiol—as the primary ingredient. CBD has seen a surge in popularity within the health and wellness industry in recent years. This non-psychoactive component of cannabis is widely recognized for its potential therapeutic benefits, particularly in skincare. Flora + Bast have fully embraced the wellness potential of this natural compound, integrating it into their diverse range of skincare products with an unwavering belief in its efficacy.
Their carefully curated range of products includes a serum, a moisturizer, and a cleanser, each delicately designed to embody the brand’s holistic approach to skincare. Each item is specifically designed to seamlessly fit into your daily skincare routine, enabling you to reap the benefits of their CBD-infused products all day, every day.
The serum from Flora + Bast is a concentrated formulation that penetrates deeply into the skin’s layers, delivering the nourishing benefits of CBD directly to the cells. It is devised to work at a cellular level, activating the skin’s natural renewal processes, and boosting its vitality.
Next in their line is a moisturizer. This CBD-infused moisturizer is designed to hydrate and nourish the skin thoroughly. It aids in combating the visible signs of aging while maintaining an optimal balance of moisture, keeping the skin plump, soft, and glowing.
The cleanser, the third key product in the Flora + Bast range, is a potent yet gentle formula. It clears the skin of impurities while ensuring it retains its natural oils and moisture. This CBD-based cleanser not only detoxifies the skin but also conditions it, promoting a healthier, more radiant complexion.
Flora + Bast firmly maintain that the utilization of CBD in their products can harmonize the skin’s oil production, ensuring the skin is neither too dry nor too oily. By establishing equilibrium in oil production, these products can assist in preventing common skin concerns such as acne, dryness, and excessive oiliness. Furthermore, they claim that their products have significant anti-inflammatory properties, which can help reduce redness, irritation, and inflammation.
Additionally, the brand purports that their CBD-infused skincare products can enhance skin elasticity. As we age, our skin becomes less elastic, leading to wrinkles and sagging. By promoting better elasticity, Flora + Bast products aim to counter these common signs of aging, providing the user with a more youthful, firm, and smooth appearance.
In conclusion, Flora + Bast has carved a niche for themselves in the competitive skincare market with their unique age-adapting, CBD-infused skincare products. They offer a comprehensive skincare solution that claims to balance oil production, reduce inflammation, and improve the skin’s elasticity, contributing to healthier, younger-looking skin.
Pacifica, a beauty brand that has carved a niche for itself in the beauty and wellness industry, is internationally renowned for its ethical stance and commitment to producing vegan and cruelty-free products. The brand’s ethos revolves around a deep and unwavering commitment to our planet and its inhabitants. The credibility of the brand gets further enhanced by their choice of ingredients and packaging – they advocate and practice the use of natural components and recyclable packaging material, emphasizing the importance of sustainability in beauty.
The brand has a wide array of beauty products that cater to diverse needs. One of the stand-out collections within their product portfolio is the cannabis collection. This innovative offering includes a mascara, a primer, a face wash, and a perfume, all infused with cannabis sativa seed oil. This not only makes the collection unique but also significantly beneficial for the skin.
The use of cannabis sativa seed oil in their products is a masterstroke by Pacifica as it is a rich source of omega fatty acids and vitamin E. Omega fatty acids, particularly Omega-3 and Omega-6, are well-known for their skin-friendly properties. They are known to reduce inflammation, skin sensitivity, and even signs of aging. Vitamin E, on the other hand, is a powerful antioxidant that helps to defend the skin against damage from external aggressors such as pollution and UV rays. Additionally, it aids in skin repair and moisturization, making it a vital ingredient for maintaining skin health.
The mascara in the cannabis collection not only enhances lash volume but also nourishes them from the root to tip. The primer creates an even skin surface, enabling the smooth application of makeup, while also providing the skin with a healthy dose of nutrients. The face wash is efficient in removing impurities without stripping the skin of its natural oils, thanks to its cannabis sativa seed oil infusion. Lastly, the perfume boasts a unique blend of scents that promises to leave a lasting impression.
In an age where consumers are increasingly conscious about the ingredients in their beauty products, Pacifica delivers on all fronts. Their commitment to using natural, vegan, and cruelty-free ingredients, combined with the use of recyclable packaging, positions them as a brand that truly cares about both your skin and the environment. The cannabis collection, with its innovative use of cannabis sativa seed oil, embodies all that Pacifica stands for, making it a must-try for those fascinated by natural, green beauty solutions.
These are just some of the many cannabis cosmetic brands that you can find online or in stores. You can also check out the links below for more information and reviews:
The Best Cannabis Beauty Products & Brands – SHEfinds
The Best Cannabis Beauty Products, According to Our Editors | Makeup.com
The 17 Best CBD Skin-Care Products of 2019 | Allure
What are some benefits of using cannabis cosmetics?
Some benefits of using cannabis cosmetics are:
They can reduce inflammation in the skin, which can help with various skin conditions, such as acne, rosacea, eczema, and psoriasis123.
They can regulate oil production in the skin, which can prevent excess sebum and clogged pores12.
They can neutralize free radical damage in the skin, which can protect it from environmental stressors and slow down the signs of aging123.
They can moisturize and nourish the skin, as they contain essential fatty acids, vitamins, minerals, and antioxidants1245.
However, not all cannabis cosmetics are created equal. The quality and quantity of the cannabis or cannabis-derived ingredients may vary depending on the source, extraction method, formulation, and testing of the products. Therefore, it is important to do some research before buying and using any cannabis cosmetic product. You should look for products that have a certificate of analysis from a third-party lab, that use full-spectrum or broad-spectrum CBD from US-grown hemp, that are free of harmful substances, and that do not make any medical claims12.
There are different ways to check if a cannabis cosmetic product has been tested for safety, depending on where you are located and where the product is made or sold. Here are some general tips that may help you:
Look for a certificate of analysis (COA) from a third-party lab that verifies the quality, purity, and potency of the product. A COA should show the amount of cannabinoids (such as CBD, CBG, etc.) and other ingredients (such as terpenes, flavonoids, etc.) in the product, as well as the absence of contaminants (such as pesticides, heavy metals, microorganisms, etc.). A COA should also have a batch number that matches the one on the product label. You can usually find a COA on the product website or by scanning a QR code on the packaging12.
Look for products that use full-spectrum or broad-spectrum CBD from US-grown hemp. Full-spectrum CBD contains all the natural compounds of the hemp plant, including trace amounts of THC (less than 0.3%). Broad-spectrum CBD contains all the natural compounds except THC. These types of CBD are considered to be more effective and beneficial than isolate CBD, which is pure CBD with no other compounds12. US-grown hemp is subject to stricter regulations and standards than hemp from other countries2.
Look for products that are free of harmful substances, such as parabens, phthalates, sulfates, artificial colors, fragrances, or preservatives. These substances can cause irritation, allergic reactions, or other health problems. You can check the ingredient list on the product label or website to see what is in the product12.
Look for products that do not make any medical claims about their benefits or effects. For example, products that claim to treat, cure, prevent, or diagnose any disease or condition are considered to be drugs and not cosmetics by the FDA. These products are illegal and may not be safe or effective. You can check the product packaging, website, or advertising to see what kind of claims are made13.
These are some general tips that may help you check if a cannabis cosmetic product has been tested for safety. However, you should also be aware of the specific regulations and requirements for cosmetic products in your country or region. For example:
In Great Britain (GB), cosmetic products must have a Responsible Person who makes sure they are safe and comply with the Cosmetics Regulation. The Responsible Person must have a UK established address and must notify the Office for Product Safety and Standards (OPSS) about their products before they are made available to consumers4.
In Australia, cosmetic products must comply with the Industrial Chemicals Act 2019 and the Industrial Chemicals (General) Rules 2019. The Australian Industrial Chemicals Introduction Scheme (AICIS) regulates the importation and manufacture of industrial chemicals in Australia, which includes ingredients used in cosmetics. The Therapeutic Goods Administration (TGA) regulates therapeutic goods in Australia, which includes products that make medical claims.
In Europe, cosmetic products must comply with Regulation (EC) No 1223/2009 on Cosmetic Products. The Responsible Person must be established in the European Union (EU) or Northern Ireland (NI) and must notify their products to the Cosmetic Products Notification Portal (CPNP) before they are placed o
Cannabis will make your skin glow in the morning
Cannabis cream, also known as CBD cream, is a topical product infused with cannabidiol, a compound found in the cannabis plant. This cream has been gaining popularity in the beauty and skincare industry due to its potential benefits, including making your skin glow.
CBD is known for its anti-inflammatory and antioxidant properties, which could be beneficial for the skin. When applied topically, it may help reduce inflammation and the effects of oxidative stress, which can make your skin appear dull and tired. By reducing these factors, cannabis cream can potentially promote a healthier and more radiant complexion.
One of the ways cannabis cream may help your skin glow is by supporting skin cell turnover. Our skin is constantly shedding dead cells and replacing them with new ones. However, as we age, this process slows down, leading to a buildup of dead skin cells on the surface. This can result in dull and lifeless skin. CBD is thought to help stimulate this cell renewal process, helping to keep the skin fresh and glowing.
CBD cream is also believed to help balance oil production. Overproduction of oil can lead to clogged pores, which can result in breakouts and a dull complexion. By regulating oil production, cannabis cream could help maintain clear, healthy skin.
Moreover, it is not uncommon for glowing skin to be a result of proper hydration. CBD creams often contain hydrating ingredients like hyaluronic acid or aloe vera, which can boost skin hydration levels, making your skin look plump, healthy, and glowing.
It’s always important to remember that not all cannabis creams are created equal. To enjoy these potential benefits, you should look for a product that contains high-quality, full-spectrum CBD and other beneficial ingredients for your skin.
Finally, while CBD cream can potentially help enhance your skin’s glow, it should be used as part of a comprehensive skincare routine, which includes proper cleansing, exfoliating, and using sunscreen to protect your skin from UV damage. As always, it’s recommended to do a patch test before using any new skincare product to ensure it does not cause any adverse reactions.
The burgeoning cannabis cosmetics industry in the United States of America is currently in an exciting phase of rapid expansion and momentum. With its roots in the broader beauty and wellness market, it has recently emerged as an elite class of its own, providing customers with a unique blend of natural and organic beauty treatments. As per recent statistics in 2022, the industry was estimated to be worth an impressive $240 million. However, this is just the tip of the iceberg as it is projected to skyrocket to a staggering $1.7 billion by the year 2027, marking a period of exceptional growth.
This exceptional and dynamic growth pattern witnessed by the cannabis cosmetics industry is not spontaneous. Instead, it’s being propelled by a host of interrelated factors. One pivotal factor that has been instrumental in this growth trajectory is the increasing legalization of cannabis across the United States. More and more states are beginning to recognize the medical benefits of cannabis and are introducing legislation to legalize its use. This shift in legal landscape has created a conducive environment for businesses in the cannabis cosmetics industry to flourish and multiply their reach.
Another significant driver of growth in the cannabis cosmetics industry is the growing popularity of natural and organic beauty products amongst consumers. The contemporary consumer is showing a clear preference for organic and natural products, turning away from chemical-laden alternatives. The consciousness towards healthier lifestyles and sustainable living is evident in their beauty choices. The cannabis plant has been embraced as an all-natural, organic ingredient, rich in beneficial compounds like CBD (Cannabidiol) and THC (Tetrahydrocannabinol), leading to its increased usage in the cosmetic industry.
Moreover, the increase in consumer awareness about the potential benefits of cannabis for skin health is another important factor contributing to the growth of this industry. Consumers are becoming more educated and discerning about the ingredients in their beauty products, and the potential health benefits they can provide. The curative, anti-inflammatory, and antioxidant properties of cannabis have been the focal point of numerous scientific research studies. It has been recognized for its potential to treat a range of skin conditions, including acne, eczema, and psoriasis, thereby boosting its popularity in the realm of skincare and cosmetics.
In conclusion, the rapid growth of the cannabis cosmetics industry in the United States is being fueled by a combination of factors. These include the increasing legalization of cannabis, growing consumer preference for natural and organic beauty products, and heightened awareness of the potential skin health benefits of cannabis. As a result, the market, currently valued at $240 million in 2022, is set to witness an explosive growth to reach $1.7 billion by 2027. The future of the cannabis cosmetics industry indeed looks promising and bright.
Cannabis cosmetics products are made with cannabis oil or cannabidiol (CBD), a non-psychoactive compound found in cannabis. CBD is said to have a number of benefits for skin health, including anti-inflammatory, antioxidant, and anti-aging properties. Cannabis cosmetics products are used to treat a variety of skin conditions, such as acne, eczema, and psoriasis. They are also said to be effective in reducing wrinkles and fine lines.
The most popular types of cannabis cosmetics products include:
Topical creams and lotions
Serums
Facial oils
Masks
Bath products
Cannabis cosmetics products are available for purchase online and in some retail stores. However, it is important to note that the FDA does not regulate cannabis cosmetics products. As a result, there is no guarantee of the safety or efficacy of these products.
King’s College London, a renowned institution in the United Kingdom, is at the forefront of a monumental research project. They are helming the largest ever independent study into cannabis use, aiming to understand the intricacies and implications of this highly debated substance’s consumption. Known for its academic rigor, integrity, and bold approach to unraveling the world’s most profound mysteries, King’s College London is the perfect organization to undertake this significant study.
The study focuses on cannabis, a substance that has long been the subject of controversy and debate. Cannabis is known for its psychoactive properties, but it’s also recognized for its potential therapeutic benefits in managing a range of health conditions, including chronic pain, multiple sclerosis symptoms, and some mental health disorders. Yet, despite its widespread use and potential benefits, the risks, particularly relating to mental health, are not fully understood.
King’s College London’s study is distinctive in that it is the largest independent study ever conducted on cannabis use. This means the study is free from any form of influence, either from the government, pharmaceutical companies, or pro-cannabis groups. Therefore, the results are expected to be unbiased, presenting a comprehensive and reliable perspective on cannabis use.
The research aims to delve into the heart of the matter, scrutinizing the potential effects of cannabis on mental health, its possible benefits, and the dangers of its misuse. The researchers will employ cutting-edge technology and sophisticated research methods to ensure the accuracy and relevance of their findings. They will use a combination of clinical trials, surveys, and other data collection methods in the quest to unravel the truth about this widely used and often demonized substance.
King’s College London’s research hopes to shed light on the often polarized and politicized discussions around cannabis. Through the provision of accurate, empirical data, it aims to contribute to evidence-based policy-making, enabling regulators to make informed decisions about the legal status of cannabis.
This research project is a testament to King’s College London’s commitment to advancing knowledge and contributing to society. By spearheading this significant study, they continue to uphold their reputation as a leading global institution of higher learning, driving forward the boundaries of human knowledge and understanding.
In conclusion, King’s College London’s groundbreaking study promises to deepen our understanding of cannabis use, bringing clarity to a topic often shrouded in controversy. Their pioneering approach, combined with their commitment to independent research, makes this project a milestone in the ongoing debate surrounding cannabis. Through this study, King’s College London continues to implement its mission of fostering academic excellence and transforming societal perspectives through rigorous, unbiased research.
The Medical Research Council has allocated over £2.5 million of funding to Cannabis & Me, a scientific study into the effects of cannabis on the human brain.
The largest independent study of its kind, Cannabis & Me will explore the environmental and biological factors that explain the different effects people experience when using cannabis.
The study, helmed by the esteemed Dr. Marta Di Forti, aims to delve into the intricate connection between an individual’s biological configuration and the impact cannabis has on them. Notably, the research project will employ a comprehensive blend of methodologies. This includes DNA genetic and epigenetics testing, an array of psychological and cognitive analysis protocols, and advanced virtual reality technology. The ultimate goal of this multifaceted research endeavor is to unravel the nexus between a user’s biological makeup and the effect the use of cannabis has on their health and overall well-being.
Dr. Di Forti and her team plan to meticulously scrutinize the interplay between various factors. They hypothesize that this complex interplay might shed light on how and why cannabis affects different individuals in distinct ways. Firstly, they will conduct DNA genetic and epigenetics testing. By studying the individual’s genetic composition and the changes that environmental factors bring about in gene expression, the team hopes to reveal the genetic predispositions that might affect an individual’s reaction to cannabis.
Next, the team will undertake a comprehensive psychological and cognitive analysis. This will involve investigating the mental health history of the subjects, their behavioral tendencies, and cognitive abilities. The team will look for any patterns or correlations between these factors and the subjects’ reactions to cannabis use.
Another novel approach of this study is the incorporation of virtual reality. The team will simulate various scenarios to evaluate how participants react to cannabis in different situations and environments. By analyzing their responses, the researchers hope to further their understanding of the drug’s effects on their mental and emotional states.
A significant aspect of this study will be to identify the environmental factors, such as a history of trauma, that might interact with genetic and epigenetic markers to influence a person’s response to cannabis. The researchers postulate that these environmental elements, in conjunction with genetic predispositions and changes in gene expression, could make certain individuals more susceptible to mental health and social issues related to cannabis use.
In effect, the study orchestrated by Dr. Di Forti seeks to shed light on the complex interrelationship between environmental influences, genetic and epigenetic markers, and the effects of cannabis on the human body and mind. By deciphering these intricate connections, the research has the potential to help predict which individuals are more likely to experience adverse mental health and social outcomes from cannabis use. This could pave the way for preventative measures, personalized treatment plans, and a deeper understanding of the multifaceted impact of cannabis on human health and society at large.
It’s estimated that over 200 million people worldwide use cannabis daily, yet we know very little about how it interacts with the human brain. With usage on the rise and legalisation potentially on the horizon, it’s more important than ever to understand the science behind the substance.
“Cannabis is consumed daily by many recreationally but also for medicinal reasons. But in the UK, the prescription of medicinal cannabis remains rare. Our study aims to provide data and tools that can make physicians in the UK and across the world more confident, where appropriate, in prescribing cannabis safely”
Dr Marta Di Forti, Senior Clinical Fellow at King’s IoPPN
As part of the study, Dr Di Forti is looking for 6,000 participants between the ages of 18-45 living in the London area that are either currently using cannabis or have used it less than 3 times or never before. The first step for participants is filling out a 40-minute survey online. More information can be found here.
In this story
Marta di Forti
Dr Marta Di Forti MD, MRCPsych, PhD
Clinical Reader in Psychosis Research
Cannabis & Me, which is led by King’s College London and funded by the Medical Research Council. It is the largest ever independent study into the effects of cannabis on the human brain12.
The study aims to explore the environmental and biological factors that explain the different effects people experience when using cannabis. It will use a combination of DNA genetic and epigenetics testing, psychological and cognitive analysis, and virtual reality to understand the link between a user’s biological makeup and the effect cannabis has on them12. The study will also try to identify the markers that are most likely to cause mental health and social problems in users2.
The study is looking for 6,000 participants between the ages of 18-45 living in the London area, who are either currently using cannabis or have used it less than three times or never before. The first step for participants is filling out a 40-minute survey online2. More information can be found on the study website.
The duration of the study depends on the group that the participant belongs to. For those who are currently using cannabis, the study will take about three hours in total, including the online survey, the face-to-face assessment, the blood sample, and the VR experience1. For those who have never used cannabis or have used it less than three times, the study will take about two hours in total, excluding the VR experience2.
The study is expected to run for two years, starting from September 20221. The researchers hope to publish their findings by 2024 and provide insights into the effects of cannabis on mental health and brain function2.
Virtual Reality technology is increasingly becoming an integral part of scientific research, and one such application of VR is in the Cannabis & Me study. This pioneering study is dedicated to investigating the effects of cannabis usage on the human brain, specifically targeting its impact on various cognitive abilities. The primary objective is to comprehend the influence of marijuana on essential brain functions, and to achieve this, researchers have designed a highly immersive Virtual Reality experience.
The VR experience serves to create an authentic simulation of a scenario where cannabis might typically be used, for instance, at a social gathering like a party or a pub. This setting is not chosen at random, but is intended to mirror real-life consumption patterns of cannabis users. The meticulous replication of these social settings is crucial in order to achieve as accurate a response as possible from the participants. The goal is to make the participants feel as if they are actually in these social environments, leading to genuine and relevant reactions.
In the VR environment, participants are introduced to various types of cannabis products. They might encounter a traditional joint, different kinds of edibles like brownies or gummies, or even vapes, all infused with cannabis. Such a wide range of products is presented to ensure that the study encompasses the numerous ways that cannabis can be consumed, thereby accounting for the unique experiences each method might offer.
Once the participants are exposed to these cannabis products in the VR experience, they are asked to rate their subjective feelings and sensations. In other words, they report how they feel physically and emotionally after the simulated use of cannabis. They might be asked about sensations of relaxation, euphoria, anxiety, or any other feelings they might be encountering. Thus, the experiment sheds light on the subjective effects of cannabis, which can be highly individual and variable, providing an in-depth understanding of the drug’s impact on users’ perceptions and experiences.
But the VR experience doesn’t stop at merely tracking subjective feelings and sensations. The research ambitiously delves into another critical area – the cognitive abilities of the participants. While the participants are under the influence of cannabis, their memory, attention, and reaction time are tested. The aim here is to observe whether and how cannabis usage affects these cognitive functions.
For instance, does the use of cannabis impair memory recall? Does it affect the ability to focus on tasks? Does it slow down the reaction time of the users? These are some of the questions that the VR experience seeks to answer. By studying these cognitive effects in a controlled VR setting, researchers can gain valuable insights into the neurological impacts of cannabis.
Exploiting the power of Virtual Reality to simulate realistic scenarios, the Cannabis & Me study aims to uncover the various effects of cannabis on the human brain. By exploring subjective experiences and cognitive abilities, this research hopes to contribute to our understanding of this widely consumed yet complex substance.
The Virtual Reality (VR) experience is an exclusive opportunity, specifically offered only to individuals who are presently using cannabis. This stipulation is due to the fact that these individuals are more apt to have developed a certain level of tolerance to the substance, thereby making it less likely for them to encounter unpleasant or adverse effects. VR, being an immersive and intensely emotional experience, might be overbearing or even disorienting for those not familiar with the altered sensations that cannabis might introduce. As such, having a previous understanding and tolerance to cannabis can significantly aid in comfortably navigating the VR landscape.
The duration of this unique VR experience is planned to be approximately one hour. Within this hour, participants will have the opportunity to engage in a wide range of virtual scenarios and environments, all while under the subtle influence of cannabis. The exact content of the VR experience can vary, but it is meticulously designed to be enriching, exciting, and intriguing for the participants. It is a rare opportunity to explore the shifting boundaries of perception and reality, which is something that VR technology, combined with the effects of cannabis, is uniquely poised to offer.
The location chosen to conduct this singular experiment is none other than the esteemed King’s College London campus. This institution is renowned for its rigorous scientific research and cutting-edge facilities, thus making it an ideal location for such an avant-garde experiment. It’s important to note that the environment in which this VR experience takes place will be safe, controlled, and carefully monitored.
The setting will be professional, with a team of researchers and medical professionals on hand to ensure the safety and well-being of the participants. Every measure will be taken to maintain a controlled environment, right from ensuring that the cannabis used is of the highest quality and does not contain any harmful substances, to controlling the VR content and monitoring the participants’ reactions throughout the experiment.
In essence, the VR experience offered to the cannabis-using participants at King’s College London is an incredibly unique and potentially enlightening opportunity. It bridges the gap between technology and altered perception, while maintaining utmost safety and control. The experiment is a testament to the progressive nature of research at King’s College London and opens up an entirely new avenue for exploring the effects of cannabis within a VR setting.
Virtual Reality (VR), a cutting-edge technology predominantly known for its applications in entertainment and gaming, is now paving the way for ground-breaking research in the field of neuroscience, specifically concerning the study of cannabis and its effects on the human brain. This innovative tool, with its capability to generate immersive environments, offers a unique platform for scientists and researchers to extensively investigate how cannabis impacts neural activities.
The interactive aspect of VR creates a controlled yet realistic environment, enabling researchers to perform comprehensive studies, observing firsthand the cognitive and behavioral changes induced by cannabis in a controlled setting. This breakthrough approach promises to offer a more holistic understanding of the subject matter, an aspect that traditional research methods would struggle to provide.
A significant advantage of using VR technology in this context is its potential to help researchers understand the complex interplay of various factors such as genetics, environment, and personality traits, and how they influence an individual’s response to cannabis consumption. For instance, genetics play a pivotal role in determining an individual’s susceptibility to the potential benefits or risks of cannabis. Certain genetic predispositions may make some individuals more prone to the therapeutic effects of cannabis, while others may be at higher risk of developing detrimental side effects.
Likewise, environmental factors and personality traits also contribute to the impact of cannabis on a person. The VR experience can replicate diverse environments and situations, providing researchers with valuable insights into how these elements affect the way one reacts to cannabis. At the same time, by taking into account personality characteristics, researchers can delve deeper into understanding how different personality types respond to cannabis. For example, an individual with a propensity for anxiety might react differently to cannabis compared to someone with a naturally calm disposition.
The benefits and risks of cannabis use are a topic of ongoing debate, and comprehensive, objective research is vital to reach a conclusive understanding. The potential risks associated with cannabis use, including the possibility of addiction and adverse effects on mental health, are areas of concern. On the other hand, the possible benefits of cannabis, such as its potential role in pain management, anxiety reduction, and its use in treating certain medical conditions, are also areas of significant interest.
In essence, the application of VR technology in studying the effects of cannabis on the human brain is an exciting prospect that opens up new avenues for research. It provides an invaluable tool for researchers to unravel the complexities of the human brain and how it responds to cannabis, considering all relevant factors. This innovative approach is expected to offer a more nuanced understanding of the potential risks and benefits of cannabis, thereby aiding in shaping future policies and guidelines related to its use.
How will the study ensure privacy and confidentiality?
Privacy and confidentiality are important aspects of the Cannabis & Me study. According to the study website, the study will ensure the following measures to protect the participants’ data1:
The study will use a secure online platform to collect and store the participants’ information. The platform will encrypt the data and assign a unique code to each participant. The code will not reveal the participant’s identity or contact details.
The study will only share the participants’ data with the research team and other authorised parties, such as the Medical Research Council, King’s College London, and the NHS. The data will be used for research purposes only and will not be sold or transferred to any third parties.
The study will comply with the General Data Protection Regulation (GDPR) and the Data Protection Act 2018, which are the laws that govern how personal data is processed in the UK. The study will also follow the ethical guidelines of King’s College London and the Health Research Authority.
The study will respect the participants’ rights to access, correct, delete, or withdraw their data at any time. The participants can contact the study team by email or phone to request any changes or queries regarding their data.
Address: Cannabis & Me, PO Box 7818, London, SE5 8RU
You can also visit the study website for more information and updates about the project. The website also has a FAQ section that might answer some of your queries.
There are many studies on cannabis and its effects on various aspects of human health and well-being. Some of the recent and relevant studies are:
A study by King’s College London and the Medical Research Council, which is the largest ever independent study into the effects of cannabis on the human brain. It uses DNA testing, psychological analysis, and virtual reality to explore how different factors influence the response to cannabis and its potential risks and benefits1.
A study by NCCIH (National Center for Complementary and Integrative Health), which is supporting several research projects on cannabis and cannabinoids, such as their effects on pain, inflammation, and thinking in people with chronic low-back pain, their synthesis in yeast, and their relationship with type 2 diabetes2.
A study by Live Science, which summarizes what researchers have learned about the health effects of cannabis over the past 20 years. It covers topics such as cannabis use and car accidents, dependence, psychosis, cognitive impairment, dropping out of school, and other illicit drug use3.
A study by CannaMD, which lists some of the top studies that prove the effectiveness of medical marijuana for various conditions, such as opioid-related deaths, cocaine use disorder, ALS, anxiety, PTSD, and cancer4.
A study by Daily Health Post, which provides over 100 cannabis cancer studies that show the anti-cancer properties of marijuana and its components, such as THC and CBD. It focuses on different types of cancer, such as brain, breast, lung, prostate, and skin cancer5.
These are some of the examples of the current research on cannabis and its implications for human health. If you want to learn more about any of these studies, you can visit their websites or read their full articles. I hope this information was interesting and helpful to you.
There are different ways to participate in a study on cannabis, depending on your eligibility, location, and interest. Here are some possible options:
You can search for ongoing clinical trials on cannabis and related topics on the NIH database. You can enter your search criteria, such as “marijuana” and your location, and see the list of studies that match your query. You can also contact the study coordinators for more information and to enroll as a volunteer1.
You can join the Cannabis & Me study, which is the largest ever independent study into the effects of cannabis on the human brain. It is led by King’s College London and funded by the Medical Research Council. It is looking for 6,000 participants between the ages of 18-45 living in the London area, who are either currently using cannabis or have used it less than three times or never before. The study will use DNA testing, psychological analysis, and virtual reality to explore how different factors influence the response to cannabis and its potential risks and benefits. You can visit the study website for more information and to fill out the online survey2.
You can participate in the SPACE study (Study on Physical Activity and Cannabis Effects), which is a new study that explores how marijuana affects workouts. It is conducted by researchers from the University of Colorado Boulder. It will enlist more than 50 paid adult volunteers who already mix cannabis and exercise for a study involving three sessions. In the first session, researchers will measure heart rate, have subjects answer a questionnaire and take some baseline fitness measurements. In the second session, participants will be asked to consume their own cannabis product at home and then complete a 30-minute exercise routine on a stationary bike in a lab. In the third session, participants will repeat the same procedure without consuming cannabis. The study will compare the effects of cannabis on exercise performance, mood, pain, and inflammation3.
You can check out other studies on cannabis that are conducted or supported by various institutions, such as universities, research centers, or government agencies. Some examples are:
Entitled “The Cannabis Disparity and Availability Study,” this comprehensive research endeavor is set to collect, scrutinize, and interpret a vast amount of data to investigate the presence or absence of discriminatory practices within the burgeoning cannabis industry of Illinois. The main objective of this study is to shed light on the extent to which discrimination pervades this rapidly growing sector, with an overarching aim of ensuring equality of opportunity and fostering a more inclusive and fair industry.
In recent years, the cannabis industry in Illinois has experienced unprecedented growth, becoming a significant economic contributor. This fast-paced development has, however, spawned concerns about potential discrimination within the industry. To that end, “The Cannabis Disparity and Availability Study” has been commissioned to rigorously examine these concerns, drawing on a wide array of data to provide an exhaustive analysis.
In this process, the study will collect data from various sources, including cannabis industry operators, employees, consumers, and other stakeholders. It will focus on areas such as hiring practices, promotional opportunities, wage disparities, and availability of cannabis products to different demographic groups. This data collection will occur across multiple stages, each meticulously designed to capture a comprehensive snapshot of the industry’s current state.
Once the data collection process is complete, the study will move into the analysis phase. Here, the collected data will be interpreted with an aim to identify any existing patterns that may indicate discrimination. This could range from wage disparities between different demographic groups to unequal opportunities for advancement within the cannabis businesses. By identifying these patterns, the study hopes to uncover any hidden biases or systemic issues that might be contributing to inequality within the industry.
Following the meticulous analysis, a comprehensive report based on the findings will be compiled. This report will detail whether discrimination exists in the Illinois cannabis industry, the extent of such discrimination, and the groups most affected by it. It will also recommend steps that stakeholders can take to remedy these issues, should they exist.
In conclusion, “The Cannabis Disparity and Availability Study” is an ambitious, far-reaching, and essential undertaking. It not only seeks to identify any discrimination within the Illinois cannabis industry but also aims to contribute to the broader discourse on equality and inclusivity within society. By delving into this critical and timely issue, the study aspires to play a significant role in making the cannabis industry a more equitable and just space for all.
The Journal of Cannabis Research is a highly prestigious and internationally recognized scientific publication that is fully open access. This means that all published content is freely accessible to all interested readers, researchers, and scholars worldwide without any financial or other barriers. By providing open access, the journal ensures that crucial research findings and insights about cannabis are widely disseminated and available to those who can benefit from them the most. Not only does this promote the global sharing of knowledge, but it also fosters the collaborative advancement of scientific understanding and innovation in cannabis research.
As a peer-reviewed journal, The Journal of Cannabis Research upholds the highest standards of academic rigor and integrity. Every article that is submitted for publication undergoes a meticulous review process by experts in the field who critically evaluate the validity, significance, and originality of the research. These expert reviewers provide constructive feedback and make recommendations for improvement, ensuring that only the most robust, credible, and impactful research is published. This rigorous peer-review process underpins the journal’s commitment to quality and excellence, contributing to its reputation as a leading source of authoritative and reliable information on cannabis research.
The Journal of Cannabis Research is also notable for the breadth and diversity of topics it covers. The journal welcomes submissions on all aspects of cannabis, from its cultivation, extraction, and processing to its physiological and psychological effects, medicinal uses, and societal implications. Whether it’s cutting-edge research on the therapeutic potential of cannabinoids in treating various diseases, in-depth studies on the genetic diversity and optimization of cannabis crops, analytical investigations on the chemical composition and potency of cannabis products, or sociological research on the legal, cultural, and public health aspects of cannabis use, the journal provides a dedicated platform for the publication of all facets of cannabis research. This comprehensive approach allows for a multidimensional understanding of cannabis and its many roles in society, health, and industry.
Furthermore, the inclusive nature of The Journal of Cannabis Research extends to its ethos of championing diverse voices and perspectives from within the global cannabis research community. It actively encourages submissions from researchers of all backgrounds, disciplines, and stages of career development, fostering a culture of inclusivity and openness that enriches the breadth and depth of its content.
In sum, The Journal of Cannabis Research is a globally respected, fully open access, peer-reviewed scientific journal that provides an invaluable platform for the dissemination of rigorous, high-quality research on all aspects of cannabis. By promoting open access, upholding academic rigor, fostering diversity and inclusivity, and embracing a wide range of research topics, the journal plays a crucial role in advancing our understanding of cannabis and driving progress in cannabis research.
The Institute of Cannabis Research, an esteemed organization in the field of cannabis studies, was launched in the year 2016. This establishment came to existence as a result of a pioneering collaborative venture among three critical parties – Colorado State University Pueblo, the state of Colorado, and Pueblo County. Each of these entities brought something unique to the table, fueling the creation of an institution that would lead the path in cannabis research.
Colorado State University Pueblo, a public university renowned for its diverse academic programs and research initiatives, was a key stakeholder in the formation of the Institute of Cannabis Research. This reputable educational institution, situated in the heart of Pueblo, Colorado, was instrumental in contributing essential academic resources and providing a conducive environment for the growth and development of the institute. The involvement of the university marked its commitment towards furthering research in emerging fields, such as cannabis studies, therefore, strengthening its position as a hub of innovation and learning.
On the other hand, the state of Colorado, where the legalization of marijuana for both medical and recreational purposes occurred relatively early, was eager to explore the potential benefits and impacts of cannabis. The state’s involvement in setting up the Institute of Cannabis Research represented its ongoing commitment to informed policy-making, based on scientific data and research. Colorado, with its progressive stance on cannabis use, became an ideal location for the establishment of such an institute, providing it with the necessary legislative support and access to a wide-ranging network of researchers and study subjects.
Furthermore, Pueblo County, known for its rich agricultural history and commitment to sustainable practices, played a critical role in this collaborative venture. The county’s involvement offered invaluable insights into the cultivation aspects of cannabis, considering its long-standing experience with farming and crop management. Pueblo County’s participation also ensured that the local community would be actively involved in the institute’s activities, fostering a healthy relationship between academia and the public.
The establishment of the Institute of Cannabis Research in 2016, thus, marked a significant milestone in the study of cannabis. The innovative partnership between Colorado State University Pueblo, the state of Colorado, and Pueblo County led to the creation of a world-class institution dedicated to researching the multifaceted aspects of cannabis, from its medical applications to its societal implications. This partnership highlighted the power of collaboration in driving progress and knowledge in an emerging field such as cannabis research.
These are some of the ways to participate in a study on cannabis. I hope this information was helpful to you.
The study, published in BMJ Supportive & Palliative Care, was a multicenter registry study of 358 cancer patients with pain who were treated with medicinal cannabis at 11 clinics in Canada and the United States. The study was observational, meaning that the researchers did not intervene in the patients’ treatment. Instead, they collected data on the patients’ pain levels, medication use, and side effects before and after they started using medicinal cannabis.
The patients were followed for an average of 12 months. During that time, they were asked to complete questionnaires every three months about their pain levels, how much pain medication they were taking, and any side effects they were experiencing.
The researchers found that the patients’ pain levels decreased significantly after they started using medicinal cannabis. The average pain score decreased from 6.2 at baseline to 4.5 at 12 months. The patients also reported using less pain medication after they started using medicinal cannabis. The average number of pain medications used per day decreased from 3.1 at baseline to 2.4 at 12 months.
The most common side effects reported by the patients were dizziness and fatigue. However, these side effects were generally mild and well-tolerated.
Overall, the study found that medicinal cannabis was a safe and effective treatment for cancer pain. The patients experienced a significant reduction in pain levels and a decrease in pain medication use after they started using medicinal cannabis. The side effects were generally mild and well-tolerated.
Additional details:
The patients in the study were a diverse group, representing a wide range of cancer types and pain severity.
The patients were treated with a variety of medicinal cannabis products, including oral capsules, sublingual sprays, and vaporizer cartridges.
The researchers found that the patients who used products with an equal balance of THC and CBD were the ones who experienced the greatest reduction in pain.
The researchers also found that the patients who used medicinal cannabis for longer periods of time were more likely to experience a reduction in pain.
Limitations of the study:
The study was observational, meaning that the researchers did not intervene in the patients’ treatment. This means that it is possible that other factors, such as the patients’ overall health or other treatments they were receiving, may have contributed to their improvement in pain.
The study did not have a control group, meaning that the researchers could not directly compare the effects of medicinal cannabis to a placebo.
The study was relatively small, with only 358 participants.
Despite these limitations, the study provides valuable evidence that medicinal cannabis may be a safe and effective treatment for cancer pain. More research is needed to confirm these findings and to identify the optimal dose and formulation of medicinal cannabis for each patient.
The study, published in BMJ Supportive & Palliative Care, researchers found medicinal cannabis to be “a safe and effective complementary treatment for pain relief in patients with cancer”.
Products with an equal balance of the active ingredients tetrahydrocannabinol (THC) and cannabidiol (CBD) seemed to be the most effective.
Cannabis plants contain both – but while THC produces a “high”, CBD does not.
Of the patients studied:
about a quarter took THC-dominant products
38% THC-CBD-balanced drugs
17% CBD-dominant products
The most common side-effects were:
dizziness
fatigue
The researchers, from McGill University, in Montreal, Harvard Medical School, in Boston and the Royal College of Surgeons in Dublin, among others, say about a third of all cancer patients and two-thirds of those who are terminally ill experience moderate to severe pain.
Painkillers are the standard treatment – but a third of cancer patients are still thought to experience pain.
Every three months for a year, the patients were asked:
how much pain they felt
how many drugs they took
After taking the cannabis medicines, they felt much less pain and noticed it interfering less with their daily life.
But more rigorous trials using a control group to compare the effects of cannabis medicines with a dummy drug are needed to confirm the findings, the researchers say.
It is very rare but since 2018 UK law has allowed the prescription of unlicensed cannabis-based medicines in very specific circumstances:
for children and adults with rare, severe forms of epilepsy
for adults with vomiting or nausea caused by chemotherapy
for people with muscle stiffness and spasms caused by multiple sclerosis (MS)
Official guidance says:
medicinal cannabis is not recommended for treating pain, or for most types of epilepsy.
more research is needed, “particularly to understand any benefits and risks of these medicines for children and young people”
A Department of Health and Social Care official said: “Licensed cannabis-based medicines are funded routinely by the NHS where there is clear evidence of their quality, safety and effectiveness.
“Like any other medicine, unlicensed cannabis-based products for medicinal use must be proved safe and effective before they can be considered for routine NHS funding.
“We are working closely with partners to establish clinical trials to test the safety and efficacy of more cannabis-based products for medicinal use to inform future NHS funding decisions.”
Medicinal cannabis can safely relieve cancer pain and curb total meds use
Products with equal balance of THC+ CBD seem to be particularly effective, data indicate
Medicinal cannabis can safely relieve cancer pain, while curbing the total number of meds and opioids taken, suggest the results of a multicentre registry study, published online in BMJ Supportive & Palliative Care.
Products with an equal balance of the active ingredients tetrahydrocannabinol (THC) and cannabidiol (CBD), rather than a dominance of either one, seem to be particularly effective, the data indicate.
The findings prompt the researchers to conclude that medicinal cannabis is a safe and complementary treatment when conventional drugs fail to touch cancer pain.
Over half of patients undergoing anticancer treatment and two thirds of those with advanced or terminal disease experience pain, say the researchers.
Powerful opioids along with other meds, such as anti-inflammatory and anticonvulsant drugs, are usually prescribed for pain relief.
But 1 in 3 patients will still experience pain, added to which the side effects of opioids include nausea, sleepiness, constipation, and respiratory depression, point out the researchers.
They therefore wanted to find out if medicinal cannabis could safely and effectively relieve cancer pain, while at the same time reducing the total number of meds and opioids taken.
They studied the treatment responses of 358 adults with cancer whose details were submitted to a multicentre registry—the Quebec Cannabis Registry in Canada—over a period of 3.5 years (May 2015 to October 2018).
The patients’ average age was 57; nearly half (48%) were men; and the 3 most common cancer diagnoses were genitourinary, breast, and bowel. Pain was the most frequently reported (72.5%) symptom that prompted a prescription of medicinal cannabis.
THC-dominant, THC:CBD-balanced, and CBD-dominant products were authorised in 24.5%, 38%, and 16.5% of patients, respectively. Taking the product by mouth was the most frequently recommended route (59%).
Patients’ pain intensity, symptoms, total number of drugs taken, and daily morphine consumption were monitored quarterly for 1 year.
Pain intensity was rated, using validated measures, on a sliding scale from none (zero) to the worst possible (10), and pain relief from none (0%) to complete (100%), with two summary measures of overall pain severity and pain interference over the preceding 24 hours.
Medicinal cannabis seemed to be safe and well tolerated, with only 15 moderate to severe side effects reported by 11 patients, 13 of which were regarded as minor. The 2 most common side effects were sleepiness, reported by 3 patients, and fatigue, reported by 2.
Two serious side effects (pneumonia and a cardiovascular event) were deemed unlikely to have been linked to medicinal cannabis. Only 5 patients stopped taking medicinal cannabis because of side effects.
“The particularly good safety profile of [medicinal cannabis] found in this study can be partly attributed to the close supervision by healthcare professionals who authorised, directed, and monitored [the] treatment,” highlight the researchers.
Statistically significant decreases were observed at 3, 6 and 9 months for worst and average pain intensity, overall pain severity, and pain interference [with daily life].
Overall, THC:CBD balanced products were associated with better pain relief than either THC-dominant or CBD-dominant products.
The total number of drugs taken also fell consistently at all the subsequent quarterly check-ups, while opioid use fell over the first three check-ups.
This is an observational study, and as such, can’t establish cause, caution the researchers. What’s more, a significant number of patients were lost to follow up over the course of the 12 months while information on the use of other prescribed meds was limited to addition or discontinuation, they acknowledge.
Nevertheless, they conclude: “Our data suggest a role for [medicinal cannabis] as a safe and complementary treatment option in patients with cancer failing to reach adequate pain relief through conventional analgesics, such as opioids.”
Medical cannabis could be “safe and complementary” treatment option
MAY 5, 2023 BRAIN TUMOUR RESEARCH4 min read
Medicinal cannabis helps relieve cancer pain and can cut down how many drugs people need, research suggests.
A new study published in BMJ Supportive & Palliative Care found that products with an equal balance of the active ingredients tetrahydrocannabinol (THC) and cannabidiol (CBD) seemed to be the most effective for pain.
Currently only specialist hospital doctors can prescribe cannabis-based medicines on the NHS, and only for a few limited conditions such as rare and severe epilepsy, vomiting or nausea caused by chemotherapy and muscle stiffness caused by multiple sclerosis (MS).
Researchers studied 358 adults with cancer over a period of three-and-a-half years. Around a quarter of patients took THC-dominant products in the study, 38% took THC:CBD-balanced drugs and 17% took CBD-dominant products. Patient pain intensity, symptoms, total number of drugs taken and daily morphine consumption were then monitored quarterly for a year.
The study found that at three, six and nine months, there were statistically significant drops in worst and average pain intensity, overall pain severity, and pain interference with daily life. Researchers concluded the data suggests a role for medicinal cannabis as“a safe and complementary treatment option in patients with cancer failing to reach adequate pain relief through conventional analgesics, such as opioids.”
It comes as a clinical trial of an oral spray containing cannabinoids to treat glioblastoma (GBM) – the most common type of primary high-grade brain tumour in adults – has opened at Leeds Teaching Hospitals NHS Trust and the Christie NHS Foundation Trust in Manchester.
The trial, funded by The Brain Tumour Charity, will investigate whether combining nabiximols (a cannabis medicine) and chemotherapy can help extend the lives of people diagnosed with recurrent GBM. It will recruit more than 230 GBM patients at 14 NHS hospitals across England, Scotland and Wales in 2023.
Dr Karen Noble, our Director of Research, Policy and Innovation, said: “We are delighted to see this clinical trial launch. Congratulations to The Brain Tumour Charity for funding this much-needed study. As highlighted in the recent All-Party Parliamentary Group on Brain Tumours Inquiry report, Pathway to a Cure – breaking down the barriers, there are a limited number of clinical trials available for brain tumour patients with only 5% of patients accessing them. Very few treatment options exist for GBM patients and we look forward to the results of this trial to see whether cannabinoid-based drugs can treat the most aggressive form of brain tumour.”
The renowned Mike Tyson, a professional boxer whose legacy in the ring is widely celebrated, first encountered cannabis during his youth. It was an era of exploration and self-discovery for him, like it is for most young people. Tyson dabbed in the realm of recreational use of cannabis, experimenting with its psychoactive effects. This was the inception of a bond that later turned into a profound therapeutic relationship as Tyson entered his later years.
However, it wasn’t until later in life, after the bright lights of the boxing ring had dimmed and the roar of the crowds had become a memory, that he truly discovered the medicinal potential of cannabis. His boxing career, despite bringing him fame and fortune, had inflicted a toll on both his physical and mental health. Tyson was not invincible to the psychological pressures that accompany celebrity status and the physical demands of a professional athlete. The consequence was a challenging battle with anxiety and depression, conditions that are often debilitating and difficult to manage.
Furthermore, his long-term participation in the grueling sport of boxing brought with it chronic pain, a constant, unignorable reminder of his days in the ring. The pain was not merely physical but was a manifestation of his emotional hardships as well. The anxiety, depression, and chronic pain created an oppressive triad that left Tyson struggling to find balance in his post-boxing life.
In his quest for relief and normalcy, Tyson found an unexpected ally in cannabis. The plant that he had once used recreationally revealed itself as a therapeutic medium, capable of providing respite from his mental and physical ailments. Through regular and controlled use, Tyson discovered that cannabis could alleviate his symptoms, making his struggles with anxiety and depression more manageable. His chronic pain, too, found relief in the therapeutic properties of the plant.
The introduction of cannabis into his wellness regimen marked a significant improvement in Tyson’s overall well-being. It was more than just a coping mechanism; it was a remedy that enhanced his quality of life. The use of cannabis allowed him to navigate his post-retirement journey with greater ease, enabling him to tackle his mental health issues and chronic pain with newfound strength.
Tyson’s journey with cannabis is not just a personal narrative; it’s a testament to the potential benefits of the plant that many still stigmatize. His experience underscores the potential of cannabis as a therapeutic tool, capable of aiding those struggling with mental health issues and chronic pain, much like himself. It’s a reminder that the path to wellness often takes unexpected turns, leading us to discover remedies in unlikely places.
Tyson has become an outspoken advocate for cannabis, sharing his personal experiences and promoting its benefits. He believes that cannabis can be a valuable tool for both medicinal and recreational use.
Tyson 2.0 Cannabis Brand
In the year 2021, the renowned personality and heavyweight boxing champion, Mike Tyson, embarked on a new entrepreneurial venture. Adding to his wide-ranging portfolio, he launched his very own cannabis brand named Tyson 2.0. The venture marks a significant step for Tyson, illustrating his evolving business acumen while also reflecting his passion for cannabis and its potential benefits. The launch of Tyson 2.0 stands as a testament to the boxing legend’s commitment to providing high-quality cannabis products to the market. Tyson, who had long been an advocate of the cannabis plant and its many uses, believes that it’s his mission to enhance public understanding about the plant. With Tyson 2.0, he aims to promote not just the recreational aspects of cannabis, but also its therapeutic properties, thus contributing positively to the ongoing discourse surrounding cannabis and its legalization. Tyson 2.0 offers an extensive range of products, each designed meticulously with a focus on quality and user experience. Their offerings include flower, which is the smokable part of the cannabis plant that most people are familiar with. Tyson 2.0 ensures that the flower products they offer are grown under optimal conditions, maintaining the integrity of the plant and preserving its natural components to provide a pure, unadulterated experience to users. The brand also offers concentrates. These are potent forms of cannabis where the plant’s beneficial compounds are extracted and condensed. It’s a product designed for those who prefer a more intense experience or require higher doses of cannabis for medicinal purposes. Tyson 2.0 ensures that their concentrates are produced using ethical, safe extraction techniques that maintain the purity and potency of the product. Adding diversity to their product line, Tyson 2.0 also provides delicious edibles. These products are perfect for those who prefer to ingest cannabis rather than smoke it. Each edible product under Tyson 2.0 is crafted carefully, maintaining the right balance between taste and potency. The brand guarantees that their edibles are created using top-grade ingredients, ensuring a delightful culinary experience that seamlessly merges with the unique effects of cannabis. Lastly, for those who prefer the traditional method of consumption, Tyson 2.0 offers pre-rolls. These are ready-to-smoke cannabis cigarettes, made from quality cannabis flowers, and rolled with attention to detail. The pre-rolls offer a convenient, hassle-free experience, especially for those new to cannabis or those who prefer not having to prepare their own. Through Tyson 2.0, Mike Tyson’s vision is clear – to provide excellent quality cannabis products while shedding light on the positive aspects of the plant. The brand stands as a significant player in the cannabis industry, highlighting Tyson’s ever-evolving entrepreneurial journey, while also contributing to the normalization and acceptance of cannabis in society.
Tyson 2.0, a brand hailed for its groundbreaking marketing strategies, has received immense praise and recognition for one campaign in particular. This campaign involved the release of a unique, ear-shaped edible product that they cheekily named “Mike Bites.” This innovative product was not only a hit due to its unique shape and the novelty it presented but also due to its clever reference to a notorious incident from the past.
In the world of boxing, few incidents are as infamous as the ear-biting episode involving the legendary boxer, Mike Tyson. It was during a highly anticipated match in 1997, when Tyson, in an unprecedented move, bit off a piece of his opponent’s ear. This shocking turn of events reverberated through the sporting world, etching this incident into the annals of boxing history. Tyson 2.0, in an ingenious move, decided to leverage this notorious event, capturing the attention of consumers around the world with their “Mike Bites” product.
The ear-shaped edibles were not just a delightful novelty item to snack on, but also a playful nod to the controversial incident. The marketing team behind Tyson 2.0 demonstrated their creativity and their deep understanding of their target audience. They knew that boxing enthusiasts and fans of Tyson would appreciate the clever reference, and that even those unfamiliar with the boxing world would be intrigued by the unique product name and its backstory.
With this innovative marketing campaign, Tyson 2.0 didn’t just succeed in garnering attention for its brand and products, it also added a layer of humor and intrigue to an otherwise ordinary product. The release of “Mike Bites” was a masterstroke, a perfect blend of humor, nostalgia, and brand storytelling. It demonstrated the brand’s willingness to think outside the box and push the boundaries of traditional marketing.
Moreover, the “Mike Bites” campaign reflects the brand’s ability to stay relevant by tapping into popular culture and historical events, thus ensuring that they always stay in the limelight. By rekindling memories of Tyson’s infamous incident, Tyson 2.0 successfully managed to capture the public’s imagination, providing a perfect example of how daring marketing can create a buzz and turn a simple product into a talking point.
In conclusion, Tyson 2.0’s innovative marketing campaigns, exemplified by the release of “Mike Bites,” showcase the brand’s ability to combine creativity with a strong grasp of their customer base. By using a playful reference to Tyson’s infamous ear-biting incident during a 1997 boxing match, they managed to create a product that stands out on the shelves and within the minds of consumers, successfully turning a notorious event into a marketing triumph.
The brand, which has been making waves in the industry, has significantly widened its influence and reached across the vast expanse of North America, firmly establishing its footprint in both the United States and Canada. The brand’s products, which are characterized by superior quality and innovative design, have become readily available to consumers in more than 20 states across the US, spanning from the cosmopolitan hubs of New York and California to the rustic charm of the Midwest. This expansion indicates not just growth, but also the brand’s commitment to making its products accessible to a wide spectrum of customers.
In Canada, the brand is strategically tapping into select provinces, ensuring its unique and diverse product line graces stores in areas where it will be most appreciated. This calculated approach demonstrates a deep understanding of the market dynamics and consumer preferences in each region, making the brand a household name in both urban centers and rural outposts.
Moreover, Tyson 2.0, a subsidiary of the aforementioned brand, has broadened its horizons by opening a coffee shop in the heart of Amsterdam, Netherlands. This new venture further amplifies the brand’s global presence and its endeavor to connect with diverse cultures across the world. This quaint coffee shop, nestled among the city’s iconic canals and historic buildings, offers a unique blend of local charm and international sophistication.
This move to Amsterdam is more than just a geographical expansion; it represents the brand’s willingness to experiment with new markets and consumer tastes. It’s a clear testament to the brand’s vision of being a global player in the industry.
By choosing Amsterdam, a city known for its vibrant café culture and discerning coffee lovers, Tyson 2.0 is not only capitalizing on an existing market but also offering a fresh perspective to the local coffee scene. With this strategic move, the brand positions itself to cater to a broad audience that ranges from local residents to international tourists, thereby cementing its global footprint.
In conclusion, the brand’s expansion across the US, Canada, and the branch-out to Amsterdam signifies its boldness in exploring new territories while remaining true to its core values of quality and customer satisfaction. This growth trajectory underscores an effective business strategy, marked by an in-depth understanding of diverse markets, a commitment to product accessibility, and the desire to engage with customers in meaningful and culturally relevant ways. It illustrates how the brand is not just selling products, but is also carving out spaces where different cultures can intersect, fostering a sense of global community.
Advocacy for Cannabis Reform
Beyond his entrepreneurial endeavors, former boxing champion Mike Tyson has found a new passion in advocating for the legalization and reform of cannabis. It is within this advocacy where Tyson’s personal convictions, business acumen, and social responsibility converge. His commitment to this cause is not limited to mere advocacy. Rather, he has taken a hands-on approach, actively engaging with the legislative process, and advocating for the rights of cannabis consumers and patients.
Tyson has always had a knack for venturing into uncharted territories and making a significant impact. Known worldwide as a fierce competitor in the boxing ring, Tyson has successfully transitioned his fighting spirit into the entrepreneurial realm, adding another layer to his multi-faceted identity. He is not just a business mogul; he is also a fervent advocate for cannabis legalization, a cause he believes in with equal parts conviction and passion.
His dedication to this cause has led him to the doors of state legislatures, standing before lawmakers, and passionately voicing his strong support for cannabis legalization. He believes that the current laws around cannabis use are too restrictive, depriving many people of the benefits they could derive from this natural resource. He asserts that these laws should be revised to make cannabis more accessible, not just for recreational consumers but also for patients who could benefit from its medicinal properties.
Tyson has frequently testified before state legislatures, urging them to reconsider their stance on cannabis. With his articulate speech and compelling arguments, he vouches for the potential medical benefits that cannabis can provide. From offering a natural alternative to synthetic painkillers to potentially helping those struggling with mental health conditions such as anxiety and depression, Tyson emphasizes that cannabis has the potential to offer a plethora of benefits if used responsibly.
Beyond his testimonies, Tyson has also taken proactive steps to make the benefits of cannabis more accessible to the public. He has established a cannabis farm and resort in California, signifying his commitment to the cause and offering a safe, controlled environment where cannabis can be used and studied. This venture not only provides a source of income but also serves as a platform for Tyson to demonstrate the potential benefits of cannabis and his belief in its positive impact on society.
In conclusion, Tyson’s advocacy for cannabis legalization goes beyond his business interests. It is a testament to his unwavering conviction in the potential benefits of cannabis and his determination to reform the current restrictive laws around it. By testifying before state legislatures and establishing his cannabis farm and resort, Tyson is not just advocating for cannabis legalization; he’s actively contributing to the fight for a more accommodating and progressive stance on cannabis use. His relentless pursuit for this cause serves as an inspiration to many who believe in the potential of cannabis, marking him as a prominent figure in the cannabis reform movement.
Tyson believes that cannabis prohibition has disproportionately affected minority communities and that legalization would create economic opportunities and reduce incarceration rates.
Impact on the Cannabis Industry
Mike Tyson’s involvement in the cannabis industry has had a significant impact. His celebrity status and personal story have helped to destigmatize cannabis and raise awareness of its potential benefits.
Tyson 2.0 has become a successful brand, contributing to the growth and diversification of the cannabis market. The company’s innovative products and marketing strategies have set a high standard for the industry.
Conclusion
Mike Tyson’s story of transformation from being an international boxing icon to a cannabis entrepreneur and advocate is truly a narrative of personal growth and societal contribution. It serves as an inspiring testament to the potential for personal redemption and transformation. This journey of his has not only uplifted his personal life but also significantly influenced the cannabis industry and the perspective of society towards it.
Born and raised in the gritty streets of Brooklyn, New York, Tyson rose to fame as one of the most formidable and influential boxing champions in the world. He was known for his relentless aggression and knockout power, earning him global recognition and multiple championship titles. His ferocity in the ring earned him the nickname “Iron Mike”, and his life was a whirlwind of media appearances, high-profile fights, and staggering wealth.
However, Tyson’s life took a turn when he discovered the medicinal properties of cannabis. This discovery led him down a new path, away from the ring and into the realm of cannabis entrepreneurship. This transition was not merely a business venture for Tyson but a personal mission. He became a passionate advocate for cannabis, endeavoring to change public perception and government legislation regarding this plant.
His dedication to this cause was not just about legitimizing cannabis as a profitable industry but also highlighting its potential therapeutic benefits. As part of his advocacy, Tyson has consistently emphasized the medical advantages of cannabis, including its potential in pain management, anxiety reduction, and even aid in neurological disorders. He aimed to shed light on how cannabis could serve as an effective alternative to traditional, often harmful, pharmaceutical drugs.
In doing so, Tyson has become a respected figure in the cannabis industry. He has used his influence to initiate dialogue and discussions about the potential benefits and uses of cannabis. He has shared his personal experiences and success stories, showing that cannabis is not just a recreational substance, but a plant with significant medicinal properties.
His contributions to the cannabis industry have gone beyond personal advocacy. Tyson has also founded Tyson Ranch, a cannabis company that aims to improve the standards of cannabis production and distribution. The company is committed to producing high-quality, responsibly sourced cannabis products, further cementing Tyson’s impact on the industry.
Additionally, Tyson’s efforts have had a tremendous social impact. He has been instrumental in shifting the narrative around cannabis, from a stigmatized substance to a plant with significant medicinal and commercial potential. His advocacy has sparked conversations, changed minds, and has even influenced legislation, showing that a single individual’s passion can lead to broader societal change.
In conclusion, Mike Tyson’s journey from a boxing champion to a cannabis entrepreneur and advocate is a remarkable story of personal transformation and societal influence. His relentless commitment to this cause has made him a respected figure in the cannabis industry, proving that there are many paths to making a difference. Tyson’s journey is a reminder that personal redemption and societal progress are not only possible but also intertwined. His story highlights how one individual’s passion can lead to larger scale societal changes, offering inspiration to many.
Mike Tyson’s cannabis brand, Tyson 2.0:
Products: Tyson 2.0 offers a variety of cannabis products, including:
Flower: Tyson 2.0 flower is available in a variety of strains, including sativa, indica, and hybrid. The flower is grown indoors and outdoors by experienced cultivators.
Concentrates: Tyson 2.0 concentrates are made with high-quality cannabis flower and are available in a variety of forms, including shatter, wax, and live resin.
Edibles: Tyson 2.0 edibles are made with high-quality cannabis and are available in a variety of forms, including gummies, chocolates, and cookies.
Pre-rolls: Tyson 2.0 pre-rolls are made with high-quality cannabis flower and are ready to smoke.
Partnerships: Tyson 2.0 partners with some of the best cannabis operators in the world to produce its products. The brand’s partners include:
Columbia Care
Cresco Labs
MedMen
Verano Holdings
Availability: Tyson 2.0 products are available in dispensaries in over 20 states in the US, as well as in select provinces in Canada. The brand also has a coffee shop in Amsterdam, Netherlands.
Mission: Tyson 2.0’s mission is to produce innovative, high-quality cannabis products that are known for their purity, precision, and wide accessibility. The brand is committed to providing consumers with an outstanding selection of products at an affordable price.
Tyson 2.0 is a relatively new brand, but it has quickly become one of the most popular cannabis brands in the US. The brand is known for its high-quality products, its innovative marketing campaigns, and its commitment to social responsibility.
Tyson 2.0 is also a vocal advocate for cannabis legalization and reform. The brand has partnered with several organizations that are working to make cannabis more accessible to patients and consumers.
Tyson’s involvement in the cannabis industry has helped to legitimize cannabis and raise awareness of its potential benefits. He is a role model for many people who are interested in using cannabis for medicinal or recreational purposes.
Cannabis gives you Mike Tyson punching power
Mike Tyson’s newest cannabis endeavor, Tyson 2.0, will bring a wide range of cannabis products to consumers across the U.S. He will serve as the chief brand officer and test every product himself1.
Tyson 2.0 launched in October 2021 and broke into the U.S. and international markets within the first year of its existence. It has successfully launched in over 100,000 retailers across 40 states and 17 countries1.
Tyson 2.0 also offers ear-shaped cannabis-infused edibles called ‘Mike Bites’, which are modelled after the infamous incident where Tyson bit off a piece of Evander Holyfield’s ear during a 1997 fight2.
Tyson has also opened a 420-acre weed resort near Desert Hot Springs in Southern California, where he plans to host music festivals, wellness retreats, and cannabis research facilities3.
Tyson has also been vocal about the benefits of psychedelics for his mental health and well-being. He credits them with helping him end his substance abuse and legal troubles4.
If you want to learn more, you can listen to his podcast, Hotboxin’ with Mike Tyson, where he interviews celebrities and comedians while smoking cannabis. You can also visit his website, Tyson 2.0, to check out his products and events.
Mike Tyson got into the cannabis business after experiencing the benefits of the plant for his health and well-being. He started his career as a cannabis entrepreneur by co-founding Tyson Holistic, a cannabis company focused on CBD products, in 20161. In 2018, he launched Tyson Ranch, a 40-acre cannabis ranch in California, where he planned to host events and conduct research2. His newest venture, Tyson 2.0, is a nationwide cannabis company that offers a wide range of products, from flower to edibles, that are tested and approved by Tyson himself2. He also serves as the chief brand officer and the chief product tester of the company2. Tyson has also been an advocate for the legalization of cannabis and the use of psychedelics for mental health2. He has a podcast called Hotboxin’ with Mike Tyson, where he interviews celebrities and comedians while smoking cannabis2. He has also partnered with other famous personalities, such as Evander Holyfield and Ric Flair, to launch their own cannabis brands under the Tyson 2.0 umbrella3. Tyson’s cannabis business is estimated to be worth over $400 million2.
Tyson Ranch is not yet open to the public. It is still under development and construction, and it will be a cannabis-themed luxury resort with various amenities and attractions123. However, Tyson Ranch does offer some cannabis products and events that are available for purchase online or at selected retailers45. You can also follow their Instagram account @tysonranchofficial to get updates on their progress and activities.
Tyson 2.0 is a cannabis company co-founded by Mike Tyson and Chad Bronstein. It offers a wide range of cannabis products, from flower to edibles, that are tested and approved by Tyson himself. The company has expanded into 20 U.S. states and Canada and sold over 4,000 pounds of cannabis flower across North America in one yearAd12.
According to my web search results, Tyson 2.0 raised over $9 million in a Series A round led by JW Asset Management in June 2022Ad1. The company plans to use the funding to acquire celebrity intellectual property, scale marketing, and distributionAd1. However, I could not find any information on how to invest in Tyson 2.0 as a public company. It seems that the company is still privately held and has not announced any plans to go public or offer shares to the general public3.
If you are interested in investing in Tyson 2.0, you might have to wait until the company decides to go public or seek more funding from private investors. Alternatively, you could try to contact the company directly and inquire about any investment opportunities. You can visit their website Tyson 2.0 to find their contact information and learn more about their products and events.
THE STORY
The undisputed heavyweight champion initially utilized cannabis to transcend to unprecedented heights.
During his prime, Mike utilized cannabis as a tool to relax his body and sharpen his focus. This was instrumental in propelling him to the pinnacle of his illustrious boxing career.
As spoken by Mike himself, the influence of cannabis on his life has been transformative, “Cannabis has always played an integral role in my life, and it’s not hyperbole to say that it has changed me for the better in more ways than one. It has been an agent of positive change both mentally and physically, and it is this life-altering potential that I yearn to share with others. I want to extend this gift to those who are also in search of relief, who are in pursuit of a natural alternative that can offer them profound healing and comfort.”
TYSON 2.0, a brand that was conceived with a vision to redefine the experience around cannabis, is thrilled to unveil three distinct lines of flower. The first is the Greenhouse and sun-grown flower, a variety of cannabis that might have a slightly lower potency, but is also more affordable and eco-friendly due to natural, energy-efficient cultivation methods. Then there’s the higher-potency indoor flower that offers a more intense and potent experience for those who seek it. This line caters to enthusiasts who value a strong, robust cannabis experience and are willing to invest in it.
The third line, named the “Toad,” is a unique and special collection of top-shelf strains that have been inspired by Tyson’s own psychedelic encounters with toad-licking. This line is a creative tribute to nature’s uncanny ability to inspire and heal, and a homage to Tyson’s own personal journey of self-discovery and transformation.
In certain markets, like Colorado, TYSON 2.0 aims to pay homage to Tyson’s illustrious boxing past in a lighthearted and playful manner. They will be introducing “Heavy Bags,” which are 1-ounce bags of cannabis retailing under $100 each. This innovative product offering is not just a nod to Tyson’s history in the boxing ring, but it also pays tribute to the fighting spirit that cannabis users often possess in their search for wellness and relief.
But the product range doesn’t end there. TYSON 2.0 will also diversify their offerings to include pre-rolled joints, making it easier for consumers to enjoy their cannabis without the hassle of rolling it themselves. Additionally, there will be a selection of cannabis-infused edibles and drinks for those who prefer more novel ways of consuming the plant. Finally, for the true connoisseurs, there will also be marijuana concentrates available, which offer a more potent and refined experience.
With this wide array of products, TYSON 2.0 is not only dedicated to offering quality cannabis but aims to cater to the varying needs and preferences of its customers, all while carrying forward Mike Tyson’s legacy of strength, determination, and personal growth.
“The Baddest Man on the Planet” Takes a Holistic Approach to Cannabis
We must roll the wheels of time back to November 22, 1986, a day that is etched in the annals of sporting history. On that fateful day, within a brief span of just 2 minutes and 35 seconds, the boxing world was left stunned as a new record was set. A record that still stands tall, a testament to an extraordinary feat achieved three decades ago.
The setting was a boxing ring, where two men, Trevor Berbick and Michael Gerard Tyson, stood toe to toe. Trevor Berbick, a seasoned boxer, known for his skill and experience, found himself on the receiving end of a flurry of rapid left hooks. And delivering these hooks, was a 20-year-old phenom, Mike Tyson, who in that very moment, was on the cusp of creating history. After a whirlwind of punches, Trevor Berbick was knocked out, and there stood in front of the world, the youngest heavyweight champion in the history of boxing. This was the moment Mike Tyson transformed from a promising pugilist into an immortalized sporting legend.
Tyson’s rise to glory was meteoric, his triumphs on the boxing ring were numerous and incredible, making him the face of the sport. However, the glory was short-lived. Mike Tyson’s world came crashing down when he was sentenced to 6 years of imprisonment in 1992. The man who was once on top of the world was now being denounced and his legacy tarnished. The bright spotlight of his victories was swiftly replaced with the bitter shock of his fall from grace.
Nevertheless, Tyson was a fighter, both inside and outside the ring. He endured the hard times, using them as the fuel to rise like a phoenix from the ashes. Despite the adversity, he didn’t allow his spirit to be broken, but instead, showed an unwavering determination to strive and succeed once again.
Fast forward to 2019, and we see a reborn Mike Tyson, a man who has learned from his past and is intent on making a positive impact on the world. Using his holistic and futuristic perspective, he turned his attention to the field of cannabis. Delving into the potential benefits of this plant, Tyson has been at the forefront of advocating for its use in treating various health conditions. His efforts in promoting a comprehensive understanding of cannabis and its potential therapeutic uses are now writing new pages in history.
In conclusion, Mike Tyson’s life and career serve as a story of redemption and reinvention. From being the youngest world heavyweight champion to surviving a prison sentence and subsequently becoming an advocate for cannabis, Tyson has continually shown resilience and adaptability. His life story is a testament to the fact that it is not about how hard you fall, but how quickly you can get back up and keep moving forward.
The Spectacular Metamorphosis of Mike Tyson (What Cannabis Has to Do with it?)
Originally recognized as one of the finest boxing champions in the annals of history, Mike Tyson endured a challenging phase of infamy that tested him to his core. It was a period of notoriety that could potentially shatter any person’s spirit, but Tyson was not just any person. Instead of wallowing in the shadows of his past, he managed to rehabilitate himself by showcasing sides of his character and talents that were largely unknown to the public.
Mike Tyson, the revered boxing champion, who once bit off Evander Holyfield’s ear in a notorious 1997 incident, underwent a remarkable transformation. He has since become a beloved comedian, speaker, motivator, and dedicated father. More notably, he emerged as one of the most influential and highly respected personalities shaping the realities of the 21st century. His journey from the boxing ring to the stage and from infamy to respectability is a testament to his indomitable spirit and resilience.
Who but Mike Tyson, a man who has journeyed through intense pain, experienced the highs of fame and the lows of failure, and occasionally succumbed to the throes of anger, could understand and advocate the benefits of cannabis better? There are many people in the world who have experienced hardship, but few have done so in the public eye and emerged as better, wiser individuals.
But Tyson’s advocacy for cannabis isn’t an isolated crusade. He is genuinely concerned about debunking the stagnant myths that portray marijuana as a highly addictive substance devoid of medicinal benefits. He uses his platform to enlighten the public about the multiple therapeutic benefits of cannabis and is an ardent supporter of those who work tirelessly in the cannabis industry.
Indeed, Tyson’s life has been a rollercoaster ride of extreme highs and lows. His boxing career, in particular, was nothing short of awe-inspiring, a fiery spectacle that was simply unrivaled. Tyson was a born champion who unleashed a beastly prowess inside the boxing ring, a level of ferocity and skill that had been previously unheard of.
Throughout his career, Tyson earned many nicknames that reflected his raw power and tenacity. Known as “Kid Dynamite” and “Iron,” these monikers celebrate his unyielding strength and dynamism. However, his erratic and controversial behavior both inside and outside the ring, his fierceness, and his dramatic imprisonment in 1992 following a rape accusation, led to the fitting nickname of “The Baddest Man on the Planet.”
Yet, is it accurate to refer to Mike Tyson as the baddest man on the planet? Despite the controversies that have dogged his career and personal life, Tyson’s narrative has taken an unexpected turn. Nowadays, labeling him as one of the kindest men on the planet seems more fitting. His transformation from a fearsome athlete to an advocate for mental health and wellness, and his journey from infamy to respectability, is a testament to his resilience and ability to change, inspire, and lead.
The Rise of Tyson Holistic Holdings
Mike Tyson, a world-renowned former boxing champion, was once infamous for his often brutal outbursts and aggressive demeanor. It is, therefore, quite ironic, even perplexing, to associate him with concepts such as “wellness” and “health.” However, like any multifaceted individual, Tyson has many different aspects to his personality, some of which have only been revealed after enduring considerable hardship in his personal life.
Nowadays, the man who was once primarily known for his prowess in the ring is making his mark in quite a different field. Mike Tyson’s latest ventures have been characterized by appearances in various forms of entertainment, from stand-up comedy shows to blockbuster movies. However, his most surprising venture has been his foray into the world of health and wellness.
In 2016, Tyson and his business partner Rob Hickman launched Tyson Holistic Holdings. With this endeavor, Mike Tyson took a significant step into the realm of holistic health and wellness, particularly in the burgeoning industry of cannabis-related businesses. The company doesn’t merely hold stakes in such businesses, but actively operates them. Tyson Holistic Holdings oversees two main companies, Tyson Holistic and Tyson Ranch, both of which are making a considerable impact in the cannabis industry.
One might wonder how Mike Tyson, known for his boxing career and controversial behavior, came to be involved in the holistic health and wellness industry, specifically in the sphere of cannabis. According to Tyson himself, the decision was simple. As soon as he was presented with the idea and contemplated the potential benefits he could provide to people through cannabis, he had no hesitation about entering this new field.
In an exclusive interview, Tyson shared his thought process behind the decision, saying, “I thought about how much good I could do by helping people with cannabis. It was a no brainer.”
But is Mike Tyson’s approach to cannabis validly defined as “holistic” and “futuristic”? Without a doubt, it is.
By definition, “holistic medicine” doesn’t merely treat the symptoms of an illness. Instead, it considers the whole individual, acknowledging the interconnectedness of physical, social, mental, and even spiritual factors. This philosophy is at the core of Tyson’s approach to cannabis and the operations of his enterprises.
As for the “futuristic” aspect, a prime example can be seen in Tyson’s innovative product line, CopperGel. The creation of this revolutionary product showcases Tyson’s forward-thinking approach to wellness and his commitment to pushing boundaries in the world of holistic health. Drawing on the interconnected philosophy of holistic medicine, Tyson’s ventures certainly are futuristic, bridging the gap between modern science and ancient holistic practices through their innovative products and strategies.
In conclusion, Mike Tyson’s foray into the world of health and wellness, especially within the field of cannabis, is not only surprising but also groundbreaking. His holistic and futuristic approach is pushing the boundaries of the industry, potentially leading the way towards a more integrated and comprehensive understanding of health and wellness.
The Launch of CopperGel Products
The pioneering venture of CopperGelline marked its inception by launching a duo of innovative products: the CopperGel® Roll-On and CopperGel® Ice With Pure Hemp Oil. These groundbreaking products represent a significant leap in the realm of natural pain relief, capturing the wellness market with their unique and potent formulations.
First introduced in April 2018, CopperGel roll-on emerged as a distinctive over-the-counter topical analgesic, created with a prime objective of providing pain relief, aptly encapsulated in the powerful motto of the product – “Knockout the Pain”. This pioneering product boasted a unique blend of active ingredients, primarily Camphor and Menthol, which have been hailed for their medicinal properties for centuries. The formulation offered dependable relief for an array of ailments from backache and arthritis to joint and muscle pain, making it a versatile solution for pain management.
The second product, CopperGel Ice with pure hemp oil, was crafted by synergistically combining the therapeutic benefits of both copper and CBD. The iconic phrase, “Nobody knows pain better than I do,” was uttered by Tyson as he introduced this novel line of products to the world. This statement underlined his personal understanding and empathy towards those suffering from pain, and his commitment to providing an effective solution.
The list of athletes who have become part of CopperGelline’s journey, endorsing Tyson’s CopperGel products, has been expanding rapidly. This illustrious list includes the likes of Brian Shaw, a four-time World’s Strongest Man, MMA superstars such as Fabricio Werdun, Urijah Faber, and Cody Garbrandt. Additionally, Eben Britton, a former NFL offensive tackle, Riley Cote, a former NHL enforcer, and Stephanie Klemons, the Global Dance Supervisor for the Broadway sell-out “Hamilton” and a Tony Award-winning Associate Choreographer, have also lent their support to the brand.
CopperGel products represent Tyson’s first significant stride into the realm of disseminating knowledge and fostering public engagement concerning the healing properties of cannabis. A key reason for focusing the first line of CopperGel products on the therapeutic properties of CBD, as opposed to THC, was to illuminate the benefits of cannabis and make it more accessible to the public. This strategic focus was also designed to cater to health-conscious individuals who may need to abstain from THC consumption or treatment due to various existing restrictions.
In addition to launching these innovative products, Tyson Holistic Holdings has made strategic investments in the water company known as CHILL. Currently, the CHILL company is making strides in developing alkaline water infused with CBD, further expanding the portfolio of wellness products aimed at enhancing health and wellbeing through natural solutions.
https://youtu.be/7MNv4_rTkfUPowerfulJRE – Joe Rogan Experience #1227 – Mike Tyson
Tyson’s Personal Quest to Promoting Cannabis as an Alternative to Opioids
Mike Tyson, the renowned former professional boxer, has undoubtedly endured a multitude of physical damages throughout his life due to his career in the ring. Consequently, he found himself with no other viable option but to resort to opiates for managing and treating his chronic pain. This has led Tyson to develop a profound understanding and personal experience of the detrimental effects that opioids can have, not only on one’s physical health but also on mental and emotional wellbeing. It’s hardly surprising then that Tyson has become a fervent advocate for promoting the therapeutic benefits of CBD – a natural, non-addictive alternative to the harmful opioids that are commonly prescribed for pain relief.
Tyson’s commitment to advocating for the healing power of CBD stems from his own personal journey. As an individual who had been engaged in the physically grueling world of boxing for over two decades, Tyson is no stranger to the wear and tear that such a physically demanding profession inflicts on the body. After two surgeries, Tyson discovered the medical benefits of marijuana. He found that consuming cannabis not only helped alleviate his pain but also enabled him to manage his anxiety, which significantly enhanced his quality of life. Therefore, Tyson firmly believes that cannabis consumption can serve as a more effective and significantly safer alternative to opiates, which had left him distraught and “all screwed up.”
However, Tyson’s unfaltering belief in the potential of cannabis to help individuals transition away from opioid addiction is not based solely on his personal experience. On February 9, 2018, he was part of a workshop at the Beckmann Center of the National Academy of Sciences titled “Cannabis and the opioid crisis: a multidisciplinary view.” The workshop brought together experts from different fields, including representatives from the National Institute on Drug Abuse, University of California San Diego, Albert Einstein College of Medicine, and Stanford University, among others. Their collective aim was to discuss and explore how cannabis could potentially help stem the escalating opioid addiction crisis that is wreaking havoc on a global scale.
Furthermore, Tyson has been proactive in his advocacy for cannabis, particularly through his pioneering efforts with Tyson Ranch, his cannabis company. He has strategically aligned himself with both veterans and professional athletes, developing numerous partnerships with representatives from major sports leagues such as the NFL, WNBA, MLB, FIFA, BIG3, UFC, and NHL. Some of the key advisors and investors Tyson has collaborated with include David Stern, former NBA Commissioner, and Al Harrington, a former NBA Player. This strategic collaboration not only promotes a broader understanding and acceptance of cannabis but also provides a platform for these athletes to share their experiences and insights.
Moreover, Tyson’s holistic approach to cannabis extends beyond athletes. He aims to promote health and wellness among one of the most vulnerable groups affected by opioid treatment – veterans. Countless veterans face the harsh reality of opioid addiction after being prescribed these medications for pain management post-combat. Tyson’s advocacy for the healing benefits of cannabis shines a light on a potential solution to this crisis, providing hope for a healthier and more sustainable treatment option.
Tyson Ranch: The Culmination of Mike Tyson’s Cannabis Entrepreneurship
Delving further into boxing legend Mike Tyson’s profound aspirations to aid veterans in the battle against opioid addiction, the man known as “Kid Dynamite” articulated his personal sentiments that he is genuinely “a big fan of veterans.” He expressed his conviction with unreserved sincerity, shedding light on the sacrifices they’ve made for the country and emphasizing the obligation the nation carries to give back in return.
He stated, “I think they’ve given a lot to our country and we should give some back in return … Especially with all of the addiction that many of them come back with,” thereby expressing his heartfelt wish to assist those who have fought for their country. Mike Tyson’s statement embodies his deeply ingrained belief in the reciprocal relationship between nation and soldier, one that should extend beyond the battlefield, particularly considering the widespread addiction issues that many veterans grapple with upon their return.
In light of this, Tyson’s entrepreneurial venture, Tyson Ranch, has truly set the standard high in terms of adopting a holistic and forward-looking perspective on the use of cannabis. Tyson is resolved to not merely empower veterans but also to offer them gainful employment at Tyson Ranch. In addition, Tyson and his dedicated team are set to invest their resources into conducting extensive research on how cannabis can play a pivotal role in assisting veterans reintegrating into society after deployment.
Tyson Ranch is an audacious project, sprawling across 407 acres of land in Southern California. It’s predicted to emerge as the ultimate marijuana resort destination, unified under the guiding principle of “Defining premium once and all for all.” This bold enterprise aims to revolutionize the cannabis industry, ushering in a new era of premium quality and exceptional service.
With Tyson Ranch serving as the latest of Tyson’s ventures, it represents nothing less than the zenith of Tyson’s cannabis entrepreneurship. It’s a multifaceted enterprise that incorporates cannabis research, education, tourist attractions, and even a music festival. All these elements are intricately interwoven around the promotion of cannabis-related health and wellness initiatives.
From the production of hemp-infused beverages and top-tier quality packaged marijuana products to the creation of cannabis-infused topical ointments, Tyson is steadfastly marching towards realizing his visionary dream of transforming Tyson Ranch into a marijuana empire. His dedication is palpable, fuelled by a potent blend of ambition and purpose.
In an interview with TODAY’s reporter Natalie Morales, Tyson maintains that, “I think weed is the miracle drug of the future.” Tyson’s experiences are a testament to this belief. From managing his own anger and debilitating social anxiety issues to alleviating the chronic pain lingering from his former boxing career, few people can claim to have such an intimate understanding of the powerful medicinal properties of marijuana as Mike Tyson. His personal journey with the herb adds a layer of authenticity to his enterprise, making him a credible advocate for the benefits of cannabis.
Music Festival, Healing, Education & Cannabis Tourism: Tyson Ranch Has Got it All!
When asked to shed light on his past battles with severe cocaine and alcohol addictions and inquired about the possible risks and consequences associated with cannabis use – whether it could potentially serve as a precarious gateway to more dangerous substances – the legendary Mike Tyson responded with a poignant sense of humility. He succinctly stated, “Doing weed got me off cocaine and all those other drinkings and all that stuff.”
Tyson’s response provides a unique perspective. It illustrates his personal journey through the dark tunnel of substance abuse and his subsequent emergence from it, attributing his recovery partly to marijuana. The former heavyweight champion suggests that cannabis, contrary to being a gateway drug, served as an exit path from his overwhelming addiction to more harmful substances like cocaine and alcohol.
As to his numerous encounters with law enforcement agencies and widespread, press-released troubles, Tyson demonstrates an aversion to dwell on his past. He refuses to acknowledge that “different guy” that he used to be, the man who often found himself on the wrong side of the law. Instead, he shows a marked preference to concentrate his energies and focus on “this guy right here and what we’re doing now.”
Tyson’s shift from the troubled past to the present indicates a profound transformation. He prefers to shed the skin of his former self, the one mired in controversy, and focus on his current endeavors, the man he has become today. This approach is reflective of his commitment to personal growth and a concentrated effort to build a more positive and meaningful future.
The notorious boxer further clarifies, “I’m not advocating for everybody to smoke pot. I’m only advocating for myself and people who’ve been experiencing pain like myself,” Tyson explains. His stance on cannabis use is not a blanket endorsement, but rather a specific recommendation for individuals who, like himself, have been locked in a struggle against pain and are desperately seeking a viable escape route.
Tyson points out that his greatest support system in his cannabis ventures (and beyond) has been his wife, Kiki. She currently holds a vital position in his company as the executive. They have been married for almost two decades, a testament to their strong bond and enduring companionship. Together, they have raised two beautiful children, further solidifying their partnership.
The support and shared vision with Kiki are evident in Tyson’s ventures. Having a strong, supportive partner has been a crucial component in his journey, not only towards sobriety but also in his business ventures in the cannabis industry. It’s a testament to the fact that the challenges of life, no matter how daunting they may appear, can be overcome with the right support system and a unwavering determination to change.
https://youtu.be/bJ24-B2TmpkMike Tyson Wants To Build A Marijuana Empire | TODAY
Mike Tyson has often been criticized for capitalizing on the burgeoning marijuana industry, with many accusing him of establishing a marijuana empire solely for financial gain. However, it’s important to understand the principles and motives that underpin the operation of Tyson Ranch, his cannabis business. One of the main objectives of Tyson Ranch’s operation is to form collaborations with local cannabis farmers. This is not just a simple partnership but an opportunity to help these local growers brand, market, and sell their products onsite.
This is a significant move because it allows Tyson Ranch to operate legally at a federal level while simultaneously shedding light on the modern-day cannabis space, which is often shrouded in misinformation and antiquated stigmas. Tyson Ranch is not setting out to cultivate marijuana plants on its premises, at least not in its current plans. This strategic operation helps differentiate them from many other cannabis businesses, focusing more on the business side of the industry than on actual cultivation.
Mike Tyson’s business partner, Rob Hickman, elucidates their business approach, “Now, a lot of people do rent land from us and grow their products on it. If they grow it to the proper standards and are licensed properly in the state, we will consider selling them our packaging, which then gives them shelf space.” This statement shows their dedication to maintaining not just quality, but also legality and ethical practices in their operations. It is not about growing the plants but supporting those who do it right.
Further explaining this novel approach to the cannabis industry, Hickman adds, “There will be testing in the university. It’s going to be about educating people on the healing benefits, how to grow, and how to be in proper business.” This underscores the business’s commitment to enlightening people about the potential benefits of cannabis, promoting responsible cultivation, and educating on proper business practices in the cannabis industry.
The concept of transforming Tyson Ranch into a comprehensive cannabis hub no longer seems like a far-fetched dream. In fact, Tyson Ranch is geared up to offer numerous opportunities for the burgeoning yet relatively new industry of cannabis tourism. This initiative is not only designed to attract tourists but also serves to further educate the public about the cannabis industry.
Apart from featuring a hotel, Tyson Ranch plans to provide a unique luxury camping experience for its visitors, aiming to construct 200 units that will allow guests to fully immerse themselves in rest and relaxation within a one-of-a-kind, cannabis-friendly environment. This ambitious venture seeks to offer a unique experience that goes beyond just accommodation, offering visitors a chance to delve into the world of cannabis in a controlled, legal, and comfortable setting.
Moreover, Tyson Ranch intends to host the Kind Music Festival, offering guests a unique blend of entertainment and education. The festival has been described as “the Lollapalooza of Cannabis,” promising a blend of music, culture, and cannabis awareness that sets it apart from other conventional music festivals.
In addition, thanks to a partnership with the 420 Games and a Wellness Expo, the Kind Festival aims to engage visitors in the growing world of cannabis. Through these partnerships, the festival doesn’t just aim to entertain, but also to educate and inform visitors about various aspects of cannabis, its uses, its potential benefits, and the future of the industry. This holistic approach aims to demystify cannabis while promoting its potential benefits and uses in a controlled and safe environment.
Tyson Ranch, Mike Tyson’s innovative and comprehensive cannabis venture, expands beyond health and wellness, encompassing cannabis education and tourism to provide an ultimate, cannabis-friendly experience. Paramount, Tyson’s novel and integrated approach aims to illuminate the multifaceted benefits of cannabis – a plant whose medicinal, recreational, economic, and environmental virtues, despite being renowned and extolled by ancient civilizations for thousands of years, have remained highly contested over the past century.
